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1400W  N-([3-(Aminomethyl)phenyl]methyl)ethanimidamide   
   dihydrochloride 
2-APB  2-aminoethoxydiphenyl borate 
8-oxodG  8-hydroxydeoxyguanosine 
A   adenine 
AACOCF3  2-oxo-1,1,1-Trifluoro-6,9-12,15-heneicosatetraene 
ACE inhibitors angiotensin converting enzyme inhibitors 
Ang II   angiotensin II 
AT1 receptor  angiotensin II type 1 receptor 
BAPTA  Ethylenedioxybis(o-phenylenenitrilo)tetraacetic acid 
BNC   binucleated cells 
BSA   bovine serum albumin 
C   cytosine 
Cand   candesartan 
CFM   calcium free medium 
CAT   catalase 
CBPI   cytokinesis block proliferation index 
DABCO  diazabicyclo octane 
DAG   diacylglycerol 
DAPI   diamidino phenylindole 
DHE   dihydroethidium 
DMEM  Dulbecco modified Eagle’s minimal essentail medium 
DMSO  dimethyl sulfoxide  
DMTU  dimethylthiourea 
DNA   deoxyribonucleic acid 
DPI   diphenyleneiodonium chloride 
DSB   double strand break 
EDTA   ethylenediamine-tetraacetic acid disodium salt 
ERK1/2  extracellular signal-regulated kinase 
EtOH   ethanol 
FCS   fetal calf serum 
Fe2+   ferrous ion 
FITC   fluorescein isothiocyanat 
FPG   formamidopyrimidine DNA glycosylase 
FRAP   ferric reducing ability of plasma/ferric reducing antioxidant power 
Fura 2-AM  Fura 2-acetoxymethyl ester 
G   guanine 
γ-H2AX  phosphorylated histone 2AX 
GPX   glutathione peroxidase 
GSH   glutathione, reduced form 
GSSG  glutathione, oxidized form 
GST   glutathione S-transferase 
h   hour 
HCl   hydrochloric acid 
HClO   hypochlorous acid 
H2DCF-DA  2’,7’-dichlorofluorescein diacetate 
HEK-293  human embionic kidney cell line 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HK-2   human kidney 2 cell line 
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H2O2   hydrogen peroxide 
hOGG1  8-oxodG DNA glycosylase 1 
HRP   horse radish peroxidase 
iNOS   inducible nitric oxide sythase 
IP3   inositol triphosphate 
IP3R   inositol triphosphate receptor 
JNK   c-Jun N-terminal kinase 
KCl   potassium chloride 
KH2PO4  monopotassium phosphate 
KOH   potassium hydroxide 
LC-MS  liquid chromatography-mass spectrometry 
LLC-PK1  porcine kidney cell line 
L-NAME  N-nitro-L-arginine methyl ester 
M   mol per liter 
µM   micromole per liter 
MAPK   mitogen-activated protein kinase 
MDCK  Madin-Darby canine kidney cell line 
MEK   mitogen-activated protein kinase kinase 
MeOH  methanol 
min   minute 
MN   micronuclei 
NAC   N-acetyl-L-cysteine 
NaCl   sodium chloride 
NADH   nicotinamide adenine dinucleotide, reduced form 
NADPH  nicotinamide adenine dinucleotide phoshate, reduced form 
NaOH   sodium hydroxide 
nm   nanometer 
nM   nanomole per liter 
NOX   NADPH oxidase subunit 
NO   nitric oxide 
NOS   nitric oxide sythase 
O2   molecular oxygen 
O2˙¯   superoxide anion 
˙OH   hydroxyl radical 
ONOO¯  peroxynitrite 
PBGD   porphobilinogen deaminase 
PBS   phosphate buffered saline 
PBST   phosphate buffered saline containing tween 
PCR   polymerase chain reaction 
PI   propidium iodide 
PI3K   phosphoinositide-3 kinase 
PKC   protein kinase C 
PLC   phospholipase C 
PMA   Phorbol 12-myristate 13-acetate 
PTX   pertussis toxin 
Rac   member of a family of hydrolases that bind and hydrolyze GTP 
RAAS   renin-angiotensin-aldosterone system 
RNA   ribonucleic acid 
ROS   reactive oxygen species 
rpm   rounds per minute 
RPMI   Roswell Park Memorial Institute medium 
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SOD   superoxide dismutase 
STIM1  Stromal interaction molecule 1 
T   thymidine 
TBS   tris buffered saline 
TEMPOL  4-Hydroxy-2,2,6,6-tetramethylpiperidine 1-oxyl 
TMB-8  8-(NN-diethylamino)octyl-3,4,5-trimethoxybenzoate 
TPG   thapsigargin 
Tris   trishydroxymethylaminomethane 
U-73122  1-[6-[((17β)-3-Methoxyestra-1,3,5[10]-trien-17-yl)amino]hexyl]-
   1H-pyrrole-2,5-dione 
U-73343  1-[6-[((17β)-3-Methoxyestra-1,3,5[10]-trien-17-yl)amino]hexyl]-
   2,5-pyrrolidinedione 
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1 Introduction 
 
 
1.1 Oxidative stress and its effects on biomolecules 
Reactive oxygen species (ROS) are ions or small molecules that include oxygen ions, 
free radicals and peroxides. In mammalian cells ROS are continuously generated 
under physiological conditions. ROS are involved in the regulation of cell growth and 
differentiation, modulation of extracellular matrix, stimulation of some gene 
expression as well as serving as second messengers in signal transductions. On the 
other hand, the damaging effects of ROS have been well described. ROS can affect 
almost all biological macromolecules of cells (75). Their effects on DNA range from 
formation of oxidized bases to single and double strand breaks (68). 
These effects are usually balanced by protective (antioxidant) mechanisms. Under 
physiological conditions, the amount of ROS which is present in the cell environment 
is easily scavenged by the antioxidant defense system of the body. This system 
comprises antioxidant enzymes, endogenous non-enzyme antioxidants and 
exogenous antioxidants from food intake. Superoxide dismutase which scavenges 
superoxide radicals, catalase, the enzyme responsible for scavenging H2O2 and 
glutathione peroxidase are among the most important examples of the enzymatic 
antioxidants. One of the most important non-enzymatic molecules which serves as a 
part of the antioxidant defense mechanism is glutathione (GSH), a tripeptide 
containing a L-cysteine, a L-glutamic acid and a glycine. The reduced thiol group of 
the cysteine acts as a strong antioxidant. Glutathione can be oxidized by reactive 
oxygen species or other oxidants to oxidized glutathione (GSSG). The oxidized form 
is more difficult to detect in the cells because the enzyme which reduces this form to 
GSH again (glutathione reductase) is constitutively active and inducible upon 
oxidative stress. In fact, the ratio of oxidized to reduced form of glutathione is a 
measure of redox balance in cells. In addition to GSH, some protein components and 
a variety of lipophilic compounds help maintaining the redox equilibrium in cells. 
Exogenous antioxidants are another part of the defense mechanism. Among them 
are some vitamins and their precursors or derivatives as well as plant derived 
polyphenols. One example of the several compounds, generally known as vitamin E 
is α-tocopherol which is a powerful antioxidant. The precursor of vitamin A, β-
carotene, is another exogenous antioxidant which has undergone several 
investigations for its beneficial effect on cancer incidence. But probably vitamin C is 
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the best known antioxidant among the public and also has shown positive effect in 
animal studies. In addition to vitamins, some other components of the human diet can 
work as antioxidants. Pelargonidin, a common anthocyanidin, chlorogenic acid, one 
of the most abundant polyphenols, epigallocatechin gallate, which is mostly found in 
green tea and resveratrol, a phytoalexin which is abundant in red wine are among the 
phytochemicals which have been proven to exert antioxidant capacity. Altogether, the 
components of the antioxidative defense mechanism are usually able to keep the 
redox balance in cells or in the body. 
Reactive oxygen species can occur in the body from food intake or smoking, 
exposition to harmful radiation, activation of signal transductions pathways which 
result in production of ROS or by metabolism of some compounds. When the 
concentration of a compound which can be metabolized to form ROS is elevated due 
to a pathophysiological condition, more ROS is produced from oxidative metabolism. 
This results in a demand for higher activation of the antioxidative defense system. If 
the defense system fails to maintain the redox balance, the cells are exposed to 
oxidative stress, which can be defined as the condition characterized by an 
imbalance between steady-state concentrations of pro- and antioxidants in favor of 
the former resulting in an overall increase in the amount of cellular ROS. As noted 
above, ROS are able to damage bio-macromolecules. ROS reaction with biological 
membranes results in lipid peroxidation, a process which gives rise to the formation 
of a variety of reactive electrophiles such as epoxides and aldehydes. 
Malondialdehyde (MDA) for example is a by-product of lipid degradation which is 
commonly used as a marker of oxidative stress. Oxidative damage to a protein, 
especially in its active site can induce the loss of the biochemical function of the 
protein. When the catalytic function of the protein is lost, it may undergo selective 
degradation. Loss of sulfhydryl (−SH) groups, formation of carbonyls, disulfide 
crosslinks, methionine sulfoxide, dityrosine cross-links, nitrotyrosine, and 
glycoxidation and lipid peroxidation adducts, are among the oxidative damages which 
ROS can cause to proteins (110). It is suggested that oxidative damage to proteins 
plays a crucial role in senescence-associated loss of physiological functions, thus 
assigning ROS-induced protein damage to age-related diseases (111). 
Reactive oxygen species can directly produce single- or double-stranded DNA 
breaks, purine, pyrimidine, or deoxyribose modifications, and DNA cross-links. It is 
estimated that in a given cell an amount of 105 oxidative lesions per day are formed 
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(38). Many forms of oxygen radicals are capable of forming oxidative base lesions. 
The hydroxyl radical in particular is able to form a number of lesions to DNA bases. 
This radical is one of the most reactive kinds of oxygen radicals which has a short 
half life and reacts quickly with cell components. To react directly with the DNA 
molecules, hydroxyl radicals have to be formed adjacent to the nucleic acid material. 
One of the most abundant DNA lesions caused by hydroxyl radical is oxidation of 
guanine at the C8 position which results in the formation of 8-oxo-7,8-dihydro-2’-
deoxyguanosine (8-oxodG) (20), an important biomarker of oxidative stress (77). Due 
to base mispairing 8-oxodG can lead to G:C to T:A transversions after replication, 
representing a point mutation which is widely found in mutated oncogenes and tumor 
suppressor genes (53, 82, 107). 
1.2 Oxidative stress in human conditions 
A number of reports in the literature implicate excessive oxidative stress and/or 
inadequate antioxidant defense in the pathogenesis of cancer, age-related disorders, 
type 2 diabetes, autoimmune diseases, reproductive disorders, cardiovascular and 
neurodegenerative diseases (4, 13, 31, 41, 103, 105-106, 118).  
1.2.1 Renin-angiotensin-aldosterone-system and DNA damage 
The renin-angiotensin-aldosterone system is an endocrine hormone system which 
maintains the blood pressure through vasoconstriction and modulation of salt and 
water homeostasis. Higher activation of this system results in hypertension and also 
in renal diseases. Epidemiological studies have revealed higher cancer incidences 
and also higher cancer mortalities in hypertensive individuals (47). 
Phaeochromocytoma, a rare tumor of the adrenal medulla is associated with 
hypertension (103). Several other studies have demonstrated that hypertension is 
associated with colorectal neoplasia (14). On the other hand, several experimental 
and epidemiological studies have demonstrated an effect of angiotensin converting 
enzyme inhibitors on cancer, although there are some other reports which could not 
find any correlation (66). A study in rats revealed that the amount of urinary 8-oxodG 
in stroke-prone spontaneously hypertensive rats was not different from the 
normotensive Wistar-Kyoto (WYK) rats at six weeks of age, but became higher than 
control after the development of severe hypertension (89). Another study showed a 
significant increase in the total chromosomal damage and the percentage of 
abnormal metaphases between spontaneously hypertensive and normal WKY rats 
(3). Furthermore, it has been reported that lymphocytes of hypertensive patients 
Introduction 11 
show higher genomic damage than those of control individuals (29, 50, 64, 117). 
Several studies have indicated that activation of the renin-angiotensin-aldosterone-
system can lead to the formation of ROS (70, 105-106). The formed ROS is possibly 
responsible for the observed DNA damage and also can contribute to the formation 
of malignancies. Most of the studies investigating the source of generated ROS were 
typically limited to the NADPH oxidase of the phagocytic cells which is a multisubunit 
enzyme comprising of two catalytic membrane-bound subunits gp91 and p22 and the 
cytosolic regulatory subunits p47phox, p67phox, p40phox, Rac1 or Rac2. In recent 
years, four homologs of gp91 (now known as Nox2) in non-phagocytic cells have 
been recognized and named Nox1, Nox3, Nox4 and Nox5 (73). NADPH oxidase is 
activated by phosphorylation of its regulatory subunit p47 which leads to the 
conformational changes in the cytosolic subunits. Then the subunits p47, p40, and 
p67 and possibly the small G-protein Rac1 migrate from the cytosol to the membrane 
and associate with the heterodimer gp91/p22 to facilitate electron transfer from 
NADPH to O2. A schematic representation of phagocyte NADPH oxidase is depicted 
in Figure 1. Different tissues express isoforms of Nox family with different localization 
and different patterns of activation. Among the family of Noxs, Nox2 is the only one 
which secrets superoxide to the outside of the cell membrane (101). To investigate 
the pathway which is involved in the production of ROS we focused on angiotensin II 
(Ang II) as one of the important components of the renin-angiotensin-aldosterone-
system. Via ROS generated by NADPH oxidase, Ang II regulates several pathways 
including protein tyrosine phosphatases and kinases, MAP kinases, transcription 
factors activation and calcium signaling (101, 113). 
Ang II is one of the oldest known peptide hormones and a major regulator of blood 
pressure. Together with aldosterone, Ang II is the active substance of the renin-
angiotensin-aldosterone system. The functional octapeptide form is produced in 
several steps from its precursor angiotensinogen which is continuously produced in 
the liver. In response to stimulation such as hypotension, decreased sodium levels or 
sympathetic activations, renin is released from the kidneys and cleaves 
angiotensinogen, producing the inactive decapeptide angiotensin I. Angiotensin I also 
undergoes cleavage by an enzyme called angiotensin converting enzyme (ACE) 
producing the active octapeptide form Ang II. (Figure 2) 
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Figure 1 Schematic representation of phagocyte NADPH oxidase activation. 
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Figure 2 Formation of angiotensin II in the body. 
Ang II mediates its effects in the cells via two receptors, Ang II type 1 receptor (AT1R) 
and Ang II type 2 receptor (AT2R), both G-protein-coupled receptors. AT1R is 
expressed in a wide variety of cells whereas AT2R is more predominant in fetal 
tissues. The AT1R mediates the major cardiovascular effects of Ang II. Some of 
these effects include vasoconstriction, secretion of aldosterone, renal sodium 
reabsorbtion, cell growth, fibrosis and thrombosis. The AT2R is involved in 
mechanisms such as vasodilatation, anti-inflammation, inhibition of cell growth, 
development of fetal tissues and apoptosis (109). Recently, our group has shown 
that perfusion of the isolated mouse kidney with concentrations of Ang II expected in 
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the kidney of hypertensive subjects is capable of damaging DNA in the primary 
kidney cells (104). This effect could be prevented using the AT1R antagonist 
candesartan which points to a role of the AT1R-dependent signaling in the 
genotoxicity of Ang II.  
An earlier study in our group has shown that treatment of several cell lines with 
properties of proximal tubules with Ang II leads to DNA damage (105). Also 
chromosomal aberrations were increased dose dependently after long-term 
incubation with Ang II. Furthermore, the genotoxic effect of Ang II could be prevented 
using the AT1R antagonist candesartan, but the AT2R antagonist PD123319 could 
not impede the Ang II-induced DNA damage significantly. In addition to single strand 
breaks and chromosomal aberrations, the formation of double strand breaks, abasic 
sites and 8-oxodG base modifications after treatment with Ang II was also confirmed 
(104). All these kinds of damages could be prevented using candesartan to block the 
AT1R signaling. 
So far no investigations have been conducted to scrutinize the pathways involved in 
the genotoxicity of Ang II.  
1.2.2 Oxidative DNA damage and aging 
There is considerable evidence that ROS production plays a role in both in vitro 
senescence and in vivo aging (84, 88). Cells obtained from laboratory mice have 
been reported to reach senescence after 4-5 cell divisions under normal cell culture 
conditions. However, when the oxygen content of the cell surroundings was reduced 
from 21 % to 3 %, the senescence was substantially delayed (94). Senescence-
associated formation of γ-H2AX foci, an indicator of DNA double strand breaks, is 
reported to be decreased when the cells are transferred to 3 % oxygen atmosphere 
or treated with antioxidants indicating the role of ROS in aging associated DNA 
double strand formation. It is also reported that the life span of mice treated with 
antioxidant drugs increases up to 25 % (33) while mice lacking the enzyme 
superoxide dismutase 1 exhibit a 30 % decrease in life expectancy (32).   
Telomeric DNA which contains TTAGGG repeats in vertebrates is another target of 
ROS induced damage. Telomeric DNA becomes shorter after each cell division. 
Below a threshold length, telomeric proteins dissociate and leave the telomers 
uncapped which results in cell growth arrest. Guanine, which is found in clusters in 
telomeric repeats, is the most easily oxidized nucleotide. Oxidized bases destabilize 
telomeric DNA resulting in accelerated telomere shortening even when DNA 
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replication does not take place. In contrast to the formation of other oxidative damage 
which can potentially be repaired, generally, somatic cells do not have telomerase 
activity to reverse the loss of telomeric repeats which makes the telomere loss 
irreversible (45, 88).    
1.2.3 Oxidative stress and Parkinson’s disease 
It is generally accepted that the pathogenesis of Parkinson's disease (PD) centers on 
the formation of reactive oxygen species and the onset of oxidative stress leading to 
oxidative damage to the substantia nigra region in the brain. Extensive postmortem 
studies have provided evidence to support the involvement of oxidative stress in the 
pathogenesis of PD. This has been shown by visualizing oxidative damage to lipids, 
proteins and DNA. Also, the activity of antioxidant systems, namely superoxide 
dismutase and GSH levels, has been shown to be decreased in this disease (54). 
Although GSH depletion alone does not result in damage to nigral neurons, it may 
increase susceptibility to subsequent exposure to free radicals. Central to many of 
the processes involved in oxidative stress and oxidative damage in PD are the 
actions of monoamine oxidase (MAO), the enzyme which is responsible for the 
enzymatic oxidation of dopamine resulting in the production of H2O2 as a by-product 
(34) ( Figure 3).  
Lymphocytes can take up, store and metabolize catecholamines (7, 27). It is reported 
that the dopamine content and tyrosine hydroxylase immunoreactivity are reduced in 
peripheral blood lymphocytes in the early stages of PD (18). On the other hand, 
dopamine content and metabolism in the peripheral lymphocytes of PD patients are 
influenced by L-Dopa administration (102). PD patients receiving a high dose of L-
Dopa had a significantly higher content of dopamine in their lymphocytes than PD 
patients who received a low dose of L-Dopa, or the healthy control. Therefore, 
peripheral blood lymphocytes can serve as a simple, easy-to-obtain and useful tool to 
study the potential genotoxic effect of dopamine.  
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Figure 3. Oxidation of dopamine via MAO or autoxidation. 
 
Cytogenetic analysis has revealed a high frequency of micronuclei (a measure of 
chromosomal aberrations, see 1.3) in blood lymphocytes of patients with untreated 
PD (77), which is of high importance because it shows that these patients not only 
suffer from damages in their central nervous system (CNS), but also outside of the 
CNS and especially in blood cells. Specific staining for centromeres demonstrated 
that most of the formed micronuclei in these patients consisted of acentric fragments 
(centromere-negative micronuclei) which points to chromosome breakage as the 
cause of micronuclei formation. As ROS are capable of inducing chromosomal 
damages, it can be hypothesized that the higher frequency of observed acentric 
micronuclei can emerge from abnormally high oxidative stress in these patients.  
Another study has demonstrated elevated amounts of oxidative DNA damage in the 
lymphocytes of PD patients before L-Dopa therapy (26). This has been proven for 
single and double strand breaks as well as formamidopyrimidine DNA glycosylase 
(FPG) sensitive sites. 
The exact mechanism of dopamine-induced damage to genetic material was not 
clear before the start of this project. We investigated the genotoxic effect of high dose 
L-Dopa therapy on the lymphocytes of PD patients and also confirmed the 
occurrence of DNA damage after dopamine treatment in vitro and then tried to reveal 
the mechanism by which dopamine exerts its genotoxic effect. 
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1.3 Quantification of genomic damage 
Among the variety of damages that ROS can cause to biological molecules, the 
damage to genetic material is of great importance because if not repaired, this kind of 
damage can eventually be inherited to the next generation of the cells. A number of 
methods are described in the literature to identify and quantify genomic damage. 
Among them, the comet assay and the micronucleus frequency test are widely used 
in genotoxicity testing, human biomonitoring and epidemiological studies.  
The comet assay was first introduced in 1984 by Östling and Johanson (93) as a 
single-cell gel electrophoresis method and later modified by Singh et al. (108). This 
method is a simple, effective and quantitative method which allows evaluation of 
strand breaks of DNA at the level of individual cells. This method is suitable for the 
evaluation of single and double strand breaks as well as a group of other damages 
generally known as alkali labile sites (incomplete excision repair sites, and apurinic or 
apyrimidinic sites, which are alkali labile and are translated into a strand break when 
exposed to the alkaline buffers of the comet assay) in a variety of biological samples 
such as cultured cells, blood lymphocytes and tissues. In this method the cells are 
embedded in an agarose gel on microscope slides and then are lysed in a high salt 
and detergent solution. This lysis process removes membranes, cytoplasm and also 
histones but leaves supercoiled DNA and some DNA-associated proteins. In the 
alkaline version of the comet assay, the next step is the denaturation of supercoiled 
DNA, which takes place in an alkaline solution. After that, an electrophoresis is 
conducted in the same high pH solution which allows the migration of broken DNA 
strands and relaxed DNA toward the positive pole of the electrophoresis field 
resulting in a comet shape formation of damaged cells. After this step the cells can 
be stained and the amount of migrated DNA can be quantified as a measure of DNA 
damage (Figure 4). 
The standard protocol of the comet assay can also be modified using different 
enzymes which are involved in the repair of some specific kind of DNA alterations. As 
an example, the use of formamidopyrimidine DNA glycosylase (FPG), which is able 
to detect the major purine oxidation product 8-oxodG as well as other altered purines 
is one of the most common methods to detect 8-oxodG base modifications. The 
same procedure is applied using endonuclease III for detecting oxidised pyrimidines 
and AP sites, 3-methyladenine DNA glycosylase for 3-methyladenine (alkA), 
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endonuclease V (UV endonuclease) for cyclobutane pyrimidine dimmers and AP 
sites and uracil DNA glycosylase to detect uracil in DNA.  
 
 
Figure 4. Two representative cells after comet assay. Cells are embedded in agarose and 
exposed to an electrical field. From cells with damaged DNA (lower picture), more DNA can 
migrate than from cells with intact nuclear DNA (upper picture).   
The micronuclous frequency test is a method for quantifying heritable genomic 
damage. This method is suitable for detecting chromosomal aberrations and 
breakage in dividing cells which are obtained from a variety of sources such as 
cultured cells, blood lymphocytes or buccal mucosa cells. Micronuclei which are 
formed as a result of chromosomal breakage or mitosis disturbances are analyzed as 
an endpoint in routine genotoxicity testing of substances and human cytogenetic 
biomonitoring. A micronucleus which is formed during mitosis contains chromosome 
fragments or whole chromosomes which are unable to migrate to the spindle poles 
during anaphase. Later in telophase, these structures get their own nuclear 
membrane and resemble a small nucleus, a micronucleus (35). A schematic picture 
of micronucleus formation and representative cells containing micronuclei are 
illustrated in Figure 5. Because formation of micronuclei only occurs when cells go 
through cell division, it is important to observe only the population of the cells which 
are actively dividing during or after the desired treatment. One possibility to achieve 
this goal is to perform the cytokinesis-block micronucleus technique using 
cytochalasin B. This inhibitor of actin polymerization blocks the separation of 
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daughter cells but not of daughter nuclei, yielding binucleated cells. By limiting the 
analysis to such binucleated cells, it can be ensured that these cells have actively 
divided since the treatment.  
 
Figure 5. A micronucleus is a broken part of a chromosome or a whole chromosome which is 
unable to migrate toward the spindle poles during mitosis. Above is the schematic ilustration 
of micronuclei formation. The lower part of the picture shows micronuclei under the 
microscope. 
Recently, micronucleus formation in peripheral blood lymphocytes has been 
correlated with cancer risk (13, 85). The authors suggest that the micronucleus 
frequency in peripheral blood lymphocytes can be a predictive indicator of cancer risk, 
implying that increased micronucleus formation is associated with early events in 
carcinogenesis. However, it is important to emphasize that this finding pertains to the 
risk of a group and not of individuals. An ongoing study is being conducted to 
investigate the potential association between micronucleus frequency in blood 
lymphocytes and cancer morbidity, as well as susceptibility to other degenerative 
diseases such as cardiovascular disease and Alzheimer disease, both of which are 
associated with increased micronuclei frequency in peripheral blood lymphocytes 
(85).
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2 Objectives 
 
A large body of evidence has accumulated for the damaging effects of ROS on DNA. 
Chromosome aberrations, DNA single and double strand breaks, base modifications 
and other kinds of DNA damage which may occur due to exposure to ROS may be 
involved in the process of malignancy development.  
Increased levels of ROS production have been observed as a consequence of 
several diseases. One example of such these diseases is hypertension which is 
becoming more endemic especially in developed countries and in some cases is 
developed due to the elevation of Ang II levels. Another example is Parkinson’s 
disease in which the prescription of the dopamine precursor L-Dopa seems to affect 
the redox balance in the patients. 
The aim of this study was to characterize the genomic damage induced by Ang II and 
dopamine and the pathways which lead to the genotoxicity of these two compounds.  
For Ang II first the genotoxic potential of the compound had to be confirmed in cell 
lines of human kidney using the comet assay and the micronucleus frequency test. 
The dependence of the observed genotoxicity on the production of ROS was to be 
demonstrated. Next, the source of produced ROS had to be identified and the 
pathway which starts with the stimulation of AT1R and ultimately results in the 
production of ROS had to be scrutinized.  
In order to investigate the genotoxicity of dopamine, potential oxidative stress and 
chromosomal aberrations in PD patients under L-Dopa therapy had to be evaluated 
to question if L-Dopa conversion to dopamine in the circulating blood can affect the 
peripheral blood lymphocytes. Also, dopamine-induced DNA damage and apoptosis 
in vitro and the dependence on ROS formation were to be confirmed. Furthermore, 
the role of receptor signaling and uptake of dopamine by the dopamine transporter 
had to be elucidated. 
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3 Materials and Methods 
 
3.1 Chemicals and reagents 
If not mentioned otherwise, all chemicals were purchased from Sigma-Aldrich 
(Taufkirchen, Germany). Cell culture media and reagents were obtained from PAA 
Laboratories GmbH (Pasching, Austria) and Invitrogen Life Technologies (Darmstadt, 
Germany). Epi life® calcium free medium was obtained from Cascade Biologics 
(Portland, OR, USA). The ERK activation inhibitor peptide was purchased from 
Calbiochem (Darmstadt, Germany). Pertussis toxin and thapsigargin were purchased 
from Enzo life sciences (Lörrach, Germany). VAS 2870 was a gift from Vasopharm 
GmbH (Würzburg, Germany). HaltTM protease and phosphatase inhibitor single-use 
cocktail was purchased from Thermo scientific (Schwerte, Germany).  
3.2 Antibodies 
The anti α-Tubulin antibody (T6199) was purchased from Sigma-Aldrich (Taufkirchen, 
Germany). The antibodies against p47phox (sc-14015) and Nox2 (sc-130543) were 
obtained from Santa Cruz Biotechnology (Heidelberg, Germany). Phospho-PKC (pan) 
(βII Ser660) antibody was purchased from Cell Signaling Technology Inc (Beverly, 
USA). Mouse monoclonal anti-phosphoserine (0023-100/PSER-16B4) was obtained 
from Biomol. Anti-AKT pS473 antibody (22650) was purchased from Rockland 
(Gilbertsville, PA, USA). Secondary antibodies were from Santa Cruz Biotechnology 
(sc-2004, sc-2005, sc-2006, sc-2020). Protein A/G PLUS-agarose (sc-2003) for 
immunoprecipitation was also obtained from Santa Cruz Biotechnology. 
3.3 Oligonucleotides 
The primers for PCR and qPCR were designed using the program Primer3 
(http://frodo.wi.mit.edu/primer3) and then ordered from MWG Biotech (Ebersberg, 
Germany). The siRNA oloigonucleotides for Nox2 (sc-35503) and Nox4 (sc-41586) 
and control siRNA (sc-37007) were purchased from Santa Cruz Biotechnology. 
3.4 Human subjects 
18 PD patients were enrolled in the study of the effect of L-Dopa therapy. Patient 
characteristics are summarized in Table 1. Patients were treated with L-Dopa in a 
dose range of 188 to 1850 mg/day and dopa decarboxylase inhibitor, either 
carbidopa (25 to 425 mg/day) or benserazid (47 to 187 mg/day) or both.  
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 PD patients Control 
Number of participants 18 12 
Sex (male/female) 12/6 1/11 
Smokers/non-smokers 1/17 1/11 
Age at study in years (range) 71.2 ± 3.2 (65–78) 
68.8 ± 4.9 (61–
80) 
Age at onset in years (range) 61.0 ± 7.8 (47–77) Not applicable 
Daily dose of L-Dopa in mg/day 
(range) 
808.68 ± 476.11 (188-
1850) 
Not applicable 
Duration of L-Dopa treatment in years 
(range) 
9.8 ± 5.2 (1.0–20) Not applicable 
Anti-oxidants/vitamin 
supplementation intake (yes/no) 
3/16 2/10 
Other medications (anti-diabetics; 
antihypertensive; thyroid 
management, etc.) (yes/no) 
11/8 7/5 
Table 1. Characteristics of the patients and control group. 
 
Further medications included catechol-O-methyl transferase (COMT) inhibitors, 
dopamine agonists, antipsychotic drugs and MAO inhibitors (Table 2.).  
Combination therapy for PD patients 
No. of 
patients 
L-Dopa (1200 mg/day) + dopa decarboxylase inhibitor (300 mg/day) 3 
L-Dopa (600 mg/day) + dopa decarboxylase inhibitor 
(150 mg/day) + COMT inhibitor (1000 mg/day) 
2 
L-Dopa (587.5 mg/day) + dopa decarboxylase inhibitor 
(110.15 mg/day) + dopamine agonist (20.10 mg/day) 
3 
L-Dopa (850 mg/day) + dopa decarboxylase inhibitor 
(212.48 mg/day) + antipsychotic (50 mg/day) 
1 
L-Dopa (775 mg/day) + dopa decarboxylase inhibitor 
(193.75 mg/day) + COMT inhibitor (950 mg/day) + dopamine agonist 
(2 mg/day) 
4 
L-Dopa (975 mg/day) + dopa decarboxylase inhibitor 
(182.81 mg/day) + COMT inhibitor (800 mg/day) + antipsychotic 
(106.25 mg/day) 
3 
L-Dopa (559.375 mg/day) + dopa decarboxylase inhibitor 
(117.38 mg/day) + MAO-B inhibitors (5.5 mg/day) + dopamine agonist 
(34.85 mg/day) 
2 
Table 2.  List of the medications taken by the Parkinson’s patients in the study. 
 
Life-partners of PD patients were also enrolled in this study, as a matched control 
group. Later 8 more male controls were also included to balance the male to female 
ratio in the control group. The study was approved by the University of Würzburg 
ethics committee and was carried out according to the declaration of Helsinki. A 
written consent was obtained from all participants prior to enrollment in the study. 
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3.5 Cell culture 
HK-2, a human kidney cell line with many properties of proximal tubular cells, was 
obtained from Dr. G. Garibotto, Nephrology Division, Department of Internal Medicine 
and Urology Division, University of Genoa, Genoa, Italy and cultured in DMEM/F12 
medium supplemented with 5 % fetal calf serum, 2 mM of L-glutamine, 1 % 
antibiotics, 10 µg/l epidermal growth factor, 5 µg/l hydrocortisone, 5 µg/l sodium 
selenate, 5 ng/l bovine pituitary extract, 5 mg/l transferrin, 5 mg/l insulin and 5 ng/l T3. 
Human embryonic kidney cells HEK-293 cells obtained from ATCC were maintained 
in DMEM medium with high glucose content supplemented with 10 % fetal calf serum, 
2 mM of l-glutamine, 0.4 % antibiotics and 2.5 % HEPES. 
The porcine epithelial cells with the characteristics of distal tubules, LLC-PK1 cells 
were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, 
USA) and maintained in DMEM medium (1 g/l glucose) supplemented with 10 % 
fetal calf serum, 2 mM L-glutamine, 2.5 % HEPES  and 0.4 % antibiotics. 
PC12, a rat pheochromocytoma cell line with many properties of primary sympathetic 
neurons, was obtained from Dr. P. Tas, Department of Anesthesiology, University of 
Würzburg, Germany, and cultured in RPMI 1640 supplemented with 10 % horse 
serum, 5 % fetal calf serum, 2 mM L-glutamine and 1 % antibiotics. 
The human B-lymphoblastoid cell line TK6 was obtained from Dr. W.J. Caspary, 
NIEHS, RTP, USA and maintained in RPMI 1640 medium supplemented with 10 % 
horse serum and antibiotics.  
NRK-52E (NRK), an epithelial rat kidney cell line with proximal tubular properties, 
was obtained from ECACC (European Collection of Cell Culture, Salisbury, UK) and 
grown in DMEM medium (4.5 g/l glucose) supplemented with 10 % fetal calf serum, 2 
mM L-glutamine, 1 % non essential amino acids and antibiotics. 
HL-60, a human promyelocytic cell line was kindly donated by Prof. Schinzel, 
Vasopharm, Wuerzburg, Germany, and was grown in RPMI 1640 medium 
supplemented with 10 % fetal calf serum, 1 % glutamine and antibiotics. 
MDCK, Madin-Darby Canine kidney cells were purchased from ATCC and 
maintained in MEM with Earl’s salts supplemented with 10 % fetal calf serum and 2 
mM L-glutamine. 
MDCK-DAT cells, MDCK cells transfected with the human dopamine transporter DAT 
(23) were a gift from Prof. G. Rudnick, Department of Pharmacology, Yale University 
School of Medicine (Atlanta, Georgia, USA) and were maintained in the same 
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medium as MDCK cells. Occasionally, 0.9 g/L of G418 was added to the medium to 
ensure the presence of the transfected gene. 
All the cells were maintained at 37 °C in a humidified atmosphere with 5 % CO2 and 
routinely split two to three times per week (PC12 two times per week)  to keep them 
in exponential growth. 
For experiments related to dopamine genotoxicity, if not mentioned otherwise, all 
genotoxicity tests were performed in PC12 cells. MDCK and MDCK-DAT cells were 
used to investigate the effect of DAT transfection on dopamine-induced genotoxicity. 
The immunocytochemistry staining (DAT-localization) was also performed in MDCK-
DAT cells because PC12 cells did not grow well on the coverslips. The quantification 
of dopamine in cell lysate was also conducted in MDCK-DAT cells due to inherent 
ability of PC12 cells to produce dopamine (7, 37) which interfered with our 
measurements. 
3.6 Collection of blood samples and Isolation and culture of human 
peripheral blood lymphocytes 
Blood samples were collected from patients and healthy controls via an indwelling 
cannula and collected in coded tubes containing heparin. Samples were transported 
from the Leopoldina Hospital, Schweinfurt (Germany) to the Department of 
Toxicology at the University of Wuerzburg (Germany) at room temperature within 2-3 
hours and processed immediately. 
Human peripheral blood lymphocytes (HPBL) were isolated by standard density 
gradient centrifugation using FicoLite H (Linaris-H, Wertheim, Germany). Blood was 
layered (1:1) onto FicoLite and centrifuged at 1600 rpm (370 g) for 30 min. at room 
temperature. The HPBL layer was transferred to a new tube and the cells were 
washed twice (1300 rpm; 250 g; 10 min) with RPMI 1640. HPBLs were cultured at a 
cell density of 1 x 106 cells/ ml in 5 ml of culture medium at 37 °C in a humidified, 5 % 
CO2 incubator. The RPMI 1640 culture medium was supplemented with 15 % fetal 
calf serum, 1 % L-glutamine, 1 % Na-pyruvate, 0.4 % penicillin/streptomycin and 1 % 
non essential amino acids. To stimulate the lymphocytes for proliferation, PHA 
(phytohemagglutinin, final concentration 10 µg/ml) was added. The lymphocytes 
were then investigated for micronuclei frequency. 
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3.7 Comet Assay 
The alkaline version of the comet assay was performed in all the experiments. After 
treatment, the cells were harvested and 20 µl of the treated cell suspension were 
mixed with 180 µl of 0.5 % low melting agarose and added to fully frosted slides that 
had been covered with a bottom layer of 1 % normal melting point agarose. The 
slides were incubated in lysis solution (2.5 M NaCl, 0.1 M EDTA, 0.01 M Tris and 1 % 
Triton X-100, 10 g/l N-lauroylsarcosine sodium adjusted to pH 10 with NaOH) at 4 °C. 
After at least one hour the slides were washed and then placed in the electrophoresis 
solution (300 mM NaOH, 1 mM EDTA, pH > 13.0) for 20 min. Then the 
electrophoresis was conducted for 20 min at 25 V (1.1 V/cm) and 300 mA. The slides 
were neutralized in 0.4 M Tris buffer (pH 7.5) and then dehydrated in methanol for 10 
min. in -20 °C. The slides were then left in 37 °C incubator to dry and stored in room 
temperature afterward. Before evaluation 20 µl of propidium iodide (CAS Nr. 25535-
16-4) solution (20 µg/ml) was added to each slide. Images of 50 randomly selected 
cells (25 per replicate slide) for each sample were analyzed with a fluorescence 
microscope (Labophot 2, Nikon, Germany) at 200-fold magnification using an image-
analysis software (Komet 5, BFI Optilas, Germany). The percentage of DNA in the 
tail was used to quantify DNA migration. 
3.8 Micronucleus frequency test 
1x105 cells/ml were incubated with test substances in 5 ml medium. After the desired 
incubation time the medium was removed and replaced by fresh culture medium 
containing cytochalasin B (2 µg/ml). This inhibitor of actin polymerization blocks the 
separation of daughter cells but not of daughter nuclei, yielding binucleated cells. By 
limiting analysis to such binucleated cells, it can be ensured that these cells have 
actively divided since the treatment. After a further 20 hours (for blood lymphocytes 
and most of the cell lines) or 48 hours (PC12), cells were harvested, applied onto 
glass slides by cytospin centrifugation and fixed in methanol (-20 °C) for at least two 
hours. Before counting, cells were stained for 3 minutes with acridine orange (62.5 
µl/ml in Sørensen buffer, pH 6.8), washed twice with Sørensen buffer (15 mM 
Na2HPO4 and 15 mM KH2PO4, pH 6.8) and mounted for microscopy. From each of 
two slides, 1000 binucleated cells were evaluated for cells containing micronuclei and 
the average was calculated. We rarely observed more than one micronucleus per cell 
under these conditions. In addition, the cytokinesis-block proliferation index, CBPI 
(number of mononucleated cells + 2 x number of binucleated cells + 3 x number of 
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multinucleated cells) / (sum of mononucleated, binucleated and multinucleated cells), 
was determined from 1000 cells of each sample. For substance combinations, 
concentrations which were described as effective in the literature and had been 
found not toxic in preliminary experiments were applied.  
3.9 Ferric reduction antioxidant power (FRAP) 
To exclude interference of potential antioxidant capacity of the compounds used for 
pharmacological inhibition with ROS-induced genotoxicity quantification, all the 
inhibitors and antagonists were tested for antioxidant activity using the ferric reducing 
antioxidant power (FRAP) method (6) which determines the reduction of a ferric 
tripyridyltriazine complex to its colored form ferrous, in the presence of antioxidants. 
Briefly, 20 µl of sample was added to 180 µl of water. Next, 600 µl of the FRAP 
reagent (1:1:10 mixture of 10 mM ferric tripyridyltriazine, 20 mM ferric chloride and 
300 mM acetate buffer) was added and the absorption at 593 nm was measured after 
3 min. The results were quantified according to a standard curve produced using 
different concentration of ferrous sulphate.  
3.10 Apoptosis assay 
Cells were incubated with the test substance in 24 well plates, which contained 
coverslips only for adherent cells (NRK). PC12 cells are weakly adherent to glass 
coverslips and were treated like suspension cells in this assay. After treatment, the 
medium was replaced with the fresh medium and cells were further incubated for 24 
hours. This duration had been found optimal for detection of apoptosis in our cell 
lines in preliminary experiments. Then, live, unfixed cells were stained by applying 5 
µM of DEVD-NucView 488 (Biotium, Inc., Hayward, USA). After 30 min cells were 
washed with PBS once. TK6 and PC12 cells were then resuspended in 20 µl of PBS 
for microscopic analysis, while coverslips with adherent cells (NRK) were mounted on 
slides using 20 µl PBS. The caspase-3 substrate DEVD-NucView 488 can rapidly 
cross the cell membrane to enter the cell cytoplasm, where it is cleaved by caspase-3 
to release a high-affinity DNA dye. The released DNA dye migrates to the cell 
nucleus to stain the nucleus brightly green upon 488 nm excitation. 500 cells per 
treatment were analyzed combining bright field for the detection of all cells with 
fluorescent illumination for detection of apoptotic cells.   
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3.11 Measurement of the cellular superoxide anion concentration  
To evaluate the release of superoxide anion, the cell-permeable fluorogenic probe 
dihydroethidium (DHE) was used. One day before the experiment, 2 x 104 cells 
were seeded on ∅12 mm coverslips in 6-well plates in 3 ml medium. After treatment 
the medium was removed and cells were washed twice with PBS. Fresh medium 
was added containing 5 µM DHE (Merck Biosciences GmbH, Schwalbach, 
Germany) and the cells were incubated for 30 min. at room temperature in the dark 
while gently shaking. After washing with PBS, the coverslips were mounted on a 
slide and observed under an Eclipse 55i microscope (Nikon GmbH, Düsseldorf, 
Germany) and a Fluoro Pro MP 5000 camera (Intas Science Imaging Instruments 
GmbH, Göttingen, Germany) at 200-fold magnification. 
3.12 SDS-PAGE and Western blot  
After treatment, the cells were harvested and lysed in homogenisation buffer (0.2 M 
mannitol, 50 mM saccharose, 10 mM HEPES, pH: 7.5). The homogenization process 
was facilitated by disruption of the cell membranes mechanically and the yielded 
suspension was then centrifuged at 14000 rpm for 30 min. at 4 °C. The protein-
containing supernatant was transferred to a clean tube and the concentration of 
protein in this solution was determined using Bradford’s method. Generally, 50 µg of 
protein per sample was loaded on a discontinuous acrylamide gel. After 
electrophoresis the gel was blotted on the PVDF membrane. The membrane was 
blocked overnight in either 5 % nonfat milk powder or 2 % bovine serum albumin in 
TBS-T buffer (5 mM TRIS, 150 mM NaCl, 0.05 % Tween-20) and then was incubated 
with primary antibody. After washing the excess of primary antibody, the horse radish 
peroxidase (HRP) conjugated secondary antibody was added followed by washing. 
After incubation with HRP substrate, the membrane was exposed to an X-ray 
sensitive film and the film was developed afterward. 
3.13 Immunoprecipitation assay 
The cells were seeded in T25 flasks one day prior to the experiment. At the day of 
the experiment the cells were treated and then washed with PBS. RIPA buffer 
supplemented with protease/phosphatase inhibitor was then used for 10 min. at 4 °C 
with gentle shaking to disrupt the cells. This process was facilitated by aspiration 
through a 21 gauge needle and the yielded suspension was then centrifuged at 
10000 g for 10 min. at 4 °C. The supernatant was then transferred to a new tube and 
incubated with the first antibody for 1 hour at 4 °C with gentle shaking. Afterward, 
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Protein A/G PLUS-Agarose was added and the tube was incubated overnight at 4 °C 
with shaking. The immunoprecipitates were collected by centrifugation at 2500 rpm 
for 5 min. at 4 °C. The pellets were washed with RIPA buffer and then resuspended 
in homogenization buffer. The yielded samples were then used for SDS-PAGE and 
Western blot as mentioned above.     
3.14 Calcium release measurement 
1 x 105 cells were cultured on coverslips in 6-well plates and treated the day after. 
The cells were then washed and incubated in new medium containing 5 µM of Fluo-4 
AM (Invitrogen, Darmstadt, Germany). After 15 min. the cells were washed in PBS 
and examined and photographed by Leica TCS SP5 confocal microscope (Leica, 
Wetzlar, Germany) which was equipped with LAS AF software (Leica, Wetzlar, 
Germany). The pictures were then analyzed using ImageJ software which could be 
downloaded free of charge from the following web address: http://rsbweb.nih.gov/ij. 
3.15 SiRNA transfection 
The cells were seeded in antibiotic free medium in 6-well plates one day prior to the 
transfection. At the day of the experiment, the cells were washed with Transfection 
Medium (sc-36868, Santa Cruz Biotechnology). SiRNA was diluted to 100 µM in 
Transfection Medium. This solution was named solution A. Transfection Reagent (sc-
29528, Santa Cruz Biotechnology) was also diluted to 100 µM with Transfection 
Medium and named solution B. Solution A and B were gently mixed and incubated 
for 45 min. at room temperature and then 800 µM of Transfection Medium was added 
to this mixture. The cells were then covered with this solution and incubated for 18 
hours at 37 °C. After this time, either the medium was changed and the cells were 
treated with angiotensin or the RNA/protein was extracted for confirming down-
regulation of the desired target.     
3.16 Subcellular protein extraction 
ProteoExtract ® subcellular proteome extraction kit (Calbiochem, Darmstadt, 
Germany) was used to extract proteins from cytosol and membrane. The cells were 
cultured in T25 flasks. The day after, the cells were treated and then washed two 
times with wash buffer for 5 min. at 4 °C. Then extraction buffer I supplemented with 
protease inhibitor cocktail was added to the cells with gentle agitation at 4 °C. After 
10 min. the supernatant was transferred to a clean tube and regarded as cytosolic 
protein fraction. Extraction buffer II supplemented with protease inhibitor cocktail was 
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added to the remaining of the cells and incubated at 4 °C for 30 min. The supernatant 
containing membrane/organelles was then transferred to another clean tube. 
3.17 RNA isolation, PCR and Real-time PCR 
The expression of mRNA was detected using the reverse transcription polymerase 
chain reaction (RT-PCR). Total RNA was isolated from the cells with the RNeasy Mini 
Kit (Qiagen, Hilden, Germany) and 2.0 µg of RNA was used for cDNA synthesis 
using Verso cDNA Synthesis Kit (Thermo scientific, Schwerte, Germany). The 
following primers were used for amplification of p47 and the house keeping gene β-
actin: p47 forward 5'-CCA CCT CCT CGA CTT CTT CA-3', p47 reverse: 5'-GAC 
ACG TCT TGC CCT GAC TT-3' (528 bp), β-actin forward: 5'-CTC TTC CAG CCT 
TCC TTC CT-3', β-actin reverse: 5'-AGC ACT GTG TTG GCG TAC AG-3' (610 bp). 
Annealing temperatures for p47 and β-actin were 54 °C and 56 °C respectively. For 
amplification of Nox2 and Nox4 genes the following primers were used: Nox2 forward: 
5'-TGC AGC CTG CCT GAA TTT CAA C-3', Nox2 reverse: 5'-GAG GCA CAG CGT 
GAT GAC AAC-3' (391 bp), Nox4 forward: 5'-CTG GTG AAT GCC CTC AAC TT-3', 
Nox4 reverse: 5'-CTG GCT TAT TGC TCC GGA TA-3' (556 bp). Annealing 
temperatures for Nox2 and Nox4 were 56 °C and 52 °C respectively. The PCR was 
performed using REDTaqTM ReadyMixTM PCR Reaction Mix (Sigma-Aldrich, 
Taufkirchen, Germany) as Taq polymerase enzyme and thermal cycler PTC 200 MJ 
research (Watertown, MA, USA). The following primers were used for amplification of 
the dopamine receptors and the house keeping gene porphobilinogen deaminase 
(PBGD): DAT forward 5'-CTG ACC AAC TCC ACC CTC AT-3', DAT reverse 5'-CAC 
AGG TAG GGA AAC CTC CA-3' (146 bp), PBGD forward 5'-ACA ACC GCG GAA 
GAA AAC-3', PBGD reverse, 5'- AGC ATC GCT ACC ACA GTG TC-3' (101 bp). 
Annealing temperature was 54 °C. Real-time PCR was conducted on the Light Cycler 
® 480 instrument (Roche Diagnostics GmbH, Mannheim, Germany) using ABsolute 
QPCR SYBR Green Mix solutions (Thermo Scientific, Schwerte, Germany) and the 
data were analyzed with the Light Cycler ® 480 software release 1.5.0 SP3 (version 
1.5.0.39).  
3.18 Immunocytochemistry staining 
For immunocytochemistry staining the cells were cultured on coverslips and treated 
the day after. After treatment the cells were washed with PBS containing 1 mM MgCl2 
and 0.1 mM CaCl2 (PBS/Mg/Ca) and fixed in cold methanol for 10 minutes. The cells 
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were then rehydrated for 5 min. in PBS/Mg/Ca and then incubated in 
permeabilization buffer (PBS/Mg/Ca plus 0.3 % Triton X-100 and 0.1 % bovine serum 
albumin) for 15 minutes. The blocking of unspecific proteins was performed in 16 % 
FCS, 0.3 % Triton X-100, 0.45 M NaCl and 20 mM sodium phosphate pH 7.4. After 
blocking, the cells were incubated with monoclonal anti-DAT antibody (Santa Cruz 
Biotechnology, Heidelberg, Germany) diluted 1:100 in blocking buffer with gentle 
shaking for 1 hour. After three times washing with permeabilization buffer, FITC 
labelled goat anti rat antibody (Santa Cruz Biotechnology, Heidelberg, Germany) was 
added (1:200 in blocking buffer) for one hour. The cells were then washed three 
times with permeabilization buffer followed by a final washing step with 5 mM sodium 
phosphate, pH 7.5 for 5 minutes. The coverslips were mounted on slides using 
Confocal-Matrix ® (Micro Tech Lab, Graz, Austria) and examined and photographed 
by Leica TCS SP5 confocal microscope and analyzed later with ImageJ software. 
The membrane to cytosol ratio of DAT was quantified. Because the membrane 
localization of DAT in polar cells like MDCK-DAT is not homogenous (49) we decided 
to measure the fluorescence intensity of four different regions of the membrane. For 
each cell, the fluorescence intensity of an 8 x 8 pixel box from four regions of the cell 
membrane at 12, 3, 6, and 9 o’clock of the cells was measured. The fluorescence 
intensity of four similar boxes from the cytosol region in close vicinity to the 
membrane boxes was also quantified. Then, the ratio of the average intensity of the 
membrane boxes to the average intensity of the cytosol boxes was calculated for 
each cell. For each treatment 50 cells were analyzed. This procedure is illustrated in 
Figure 6.     
3.19 Measurement of released H2O2 in medium 
H2O2 measurement was conducted according to the method described by Pick et al 
(98) with some modifications. PC12 cells were cultured the day before the 
experiment. The cells were washed with PBS and then covered with phenol red 
solution (140 mM NaCl, 10 mM potassium phosphate buffer, pH: 7.0, 5.5 mM 
dextrose, 0.56 mM phenol red and 19 U/ml horse radish peroxidase). The cells were 
then treated with PBS (negative control), 100 µM of dopamine or 1.56, 3.13, 6.25 and 
12.5 µM of H2O2 (for standard curve) for 30 min. At the end of treatment the cells 
were collected and centrifuged. The supernatant was collected in a new tube and 1 N 
NaOH was added. The absorbance of this solution was read at 600 nM. To account 
for directly dopmanine-mediated absorption at the applied wavelength, 100 µM of 
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dopamine was added to the supernatant of a negative control sample and the 
measured absorbance (never more than a few percents of the total absorbance) was 
subtracted from absorbance of the dopamine treated samples. The pellet was used 
for determination of protein concentration using Bradford’s method. The amount of 
released H2O2 was calculated from the standard curve and was related to protein 
content of each sample. 
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Figure 6.  Schematic representation of a cell to show the boxes used for quantification of 
localization of the dopamine transporter (DAT) in the cell membrane and the cytosol.  
3.20 Statistics 
Statistical calculations were performed using Statistica 8 (StatSoft (Europe) GmbH, 
Hamburg, Germany). If not mentioned otherwise, data from at least 3 independent 
experiments ± standard deviation are depicted. Statistical significance among 
multiple groups was tested with Kruskal-Wallis test. Individual groups were then 
tested using the Mann Whitney U-test and results were considered significant if the p-
value was ≤ 0.05. For quantification of immunocytochemical data (DAT localization) 
and calcium measurement, student’s T-test was used. The p-value of ≤ 0.05 was 
considered significant. 
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4 Results 
 
4.1 Angiotensin II 
 
4.1.1 Genotoxicity of Ang II 
The genotoxicity of Ang II in LLC-PK1, HEK-293 cells and HK-2 cells was evaluated. 
Two methods were used to detect Ang II-induced DNA damage, the comet assay and 
the micronucleus test. Both methods revealed a significant increase of DNA damage 
after incubation of cells with Ang II (Figure 7).  
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Figure 7 Ang II-induced DNA damage measured by micronucleus frequency test after 
incubating LLC-PK1 cells with the indicated concentrations of Ang II for 4 h. MN = micronuclei, 
BNC = binucleated cells. * p ≤ 0.05 vs. Ang 0 nM (Mann-whitney U-test). 
To verify how much time is needed for Ang II to exert its genotoxic effect, a time 
course experiment was conducted in HEK-293 cells. The cells started to show a 
genotoxic response in the comet assay after 30 min. which was significant after 60 
min. of treatment (Figure 8). 
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Figure 8 Ang II-induced DNA damage measured with the comet assay after incubating HEK-293 
cells with 200 nM of Ang II for the indicated time. * p ≤ 0.05 vs. Ang 0 min (Mann-whitney U-test).  
 
4.1.2 AT1R antagonist candesartan 
Hypothesizing that the genotoxic effects of Ang II are mediated by the Ang II type 1 
receptor (AT1R), we tested the specific AT1R antagonist candesartan (Cand). Cand 
completely prevented the Ang II-induced DNA damage in HK-2 cells in the comet 
assay (Figure 9) as well as in the micronucleus frequency test (not shown). This 
suggests a fundamental role of the AT1R in Ang II-induced DNA damage.  
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Figure 9 DNA damage measured with the comet assay after treatment of HK-2 cells with 200 nM 
Ang II with or without co-incubation with the indicated concentrations of the AT1R antagonist 
candesartan for 4 h. * p ≤ 0.05 vs. Ang II treated sample (Mann-whitney U-test). 
 
4.1.3 ROS production and antioxidants 
It was shown in our group that treatment of cells with Ang II leads to the production of 
reactive oxygen species measurable with flow cytometry (105). To reveal which kind 
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of reactive oxygen species are formed after Ang II treatment, LLC-PK1 cells were 
stained with the superoxide specific dye dihydroethidium. The cells were then 
inspected under the fluorescence microscope. The Ang II-treated cells showed a 
higher production of superoxide in comparison to the control sample. This effect 
could be prevented using the superoxide radical scavenger TEMPOL (Figure 10). 
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Figure 10 Induction of superoxide radical production visualized with help of the superoxide 
specific dye dihydroethidium in LLC-PK1 cells. Cells were treated with I) PBS, II) 200 nM Ang II 
and III) 200 nM Ang II + 50 µM of the superoxide radical scavenger TEMPOL.  
To confirm which ROS exactly are responsible for the genotoxicity of Ang II, we 
investigated the effect of two antioxidant enzymes as well as of two antioxidant 
compounds with different antioxidant properties. Our results showed that catalase, 
the enzyme which removes an excess of hydrogen peroxide can reduce DNA 
damage caused by Ang II in HEK-293 cells. Furthermore, pre-incubation of cells with 
catalase (allowing for catalase uptake by the cells) had a more efficient protective 
effect (Figure 11). 
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Figure 11 Micronucleus formation after incubation of HEK-293 cells with 200 nM Ang II and 300 
U of the hydrogen peroxide scavenger enzyme catalase for 4 h. MN = micronuclei, BNC = 
binucleated cells. * p ≤ 0.05 vs. Ang II treated sample (Mann-whitney U-test). 
Superoxide dismutase (SOD), the enzyme which conducts the dismutation of 
superoxide to hydrogen peroxide caused no reduction of DNA damage either with 
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pre- or co-incubation (Figure 12). This enzyme, which cannot enter the cells 
nevertheless proved its potency in reducing the DNA damage caused by PMA. PMA 
is known to induce extracellular superoxide release. However, TEMPOL, a mimetic of 
SOD which can cross the cell membrane, was able to protect the cells against 
genotoxic effects of Ang II completely (Figure 13). This led us to the conclusion that 
the radicals which are responsible for DNA damage are formed and act inside the 
cells and are not secreted out of the cells. This point will be later discussed with 
regard to the NADPH oxidase enzyme isoforms. 
To determine the contribution of hydroxyl radicals in Ang II induced DNA damage, 
N,N′ -dimethylthiourea (DMTU), an antioxidant which shows hydroxyl radical 
scavenging properties was used. The data in Figure 14 illustrate that DMTU was able 
to decrease the genotoxic effects of Ang II, but not completely. 
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Figure 12 Micronucleus formation after incubation of HEK-293 cells with 200 nM Ang II and 300 
U of the superoxide scavenger enzyme superoxide dismutase (SOD) for 4 h.  32 µM PMA 
served as the positive control. MN = micronuclei, BNC = binucleated cells. * p ≤ 0.05 vs. PMA 
treated sample (Mann-whitney U-test). 
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Figure 13 Micronucleus formation after incubation of HEK-293 cells with 200 nM of Ang II and 
the indicated concentrations of the superoxide dismutase mimetic TEMPOL for 4 h. MN = 
micronuclei, BNC = binucleated cells. * p ≤ 0.05 vs. Ang II treated sample (Mann-whitney U-test). 
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Figure 14 DNA damage measured by comet assay after treatment of HEK-293 cells with 200 nM 
Ang II with or without the indicated concentration of hydroxyl radical scavenger DMTU for 4 h. * 
p ≤ 0.05 vs. Ang II treated sample (Mann-whitney U-test). 
 
4.1.4 Inhibition of NOS and its effect on the genotoxicity of Ang II 
Ang II is known to increase nitric oxide synthase (NOS) and NADPH oxidase activity 
as two possible sources of ROS production. To verify if the NOS family is involved in 
Ang II-induced genotoxicity, L-NAME as a general inhibitor of the family and 1400W, 
a specific inhibitor of inducible NOS were added to the cells together with Ang II. The 
depicted data in Figure 15 and Figure 16 show that none of the inhibitors were able 
to protect the cells against the genotoxic effect of Ang II, implying that NOS does not 
play a role in the genotoxicity of Ang II. 
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Figure 15 Micronuclei formation after treatment of HEK-293 cells with 200 nM of Ang II with or 
without co-incubation with the indicated concentrations of NOS inhibitor, Nω-Nitro-L-arginine 
methyl ester hydrochloride (L-NAME) for 4 h. MN = micronuclei, BNC = binucleated cells. 
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Figure 16 Micronuclei induced by 4 h treatment of HK-2 cells with 200 nM Ang II and the 
indicated concentrations of the specific inducible NOS inhibitor 1400W. MN = micronuclei, BNC 
= binucleated cells. 
 
4.1.5 The effect of NADPH oxidase inhibition on the genotoxicity of Ang II 
NADPH oxidase was also targeted with the same strategy using 
diphenyleneiodonium chloride (DPI), an inhibitor of flavoprotein enzymes such as 
NADPH oxidase and VAS 2870, a novel inhibitor of NADPH oxidase. As depicted in 
Figure 17, DPI was able to reduce the DNA damage in the cells, leading us to the 
conclusion that superoxide radicals which are produced by this enzyme may play a 
role in the genotoxicity of Ang II. VAS 2870 which is supposed to exclusively inhibit 
NADPH oxidase reduced the DNA damage caused by Ang II to the control level 
(Figure 17) which confirms the hypothesis that NADPH oxidase is the source of ROS 
which is responsible for genotoxicity of Ang II. 
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Figure 17 DNA damage measured in the micronucleus frequency test after 4 h treatment of HK-
2 cells with 200 nM Ang II with or without co-incubation with the indicated concentrations of 
the flavoprotein enzyme inhibitor diphenyleneiodonium chloride (DPI) and with the NADPH 
oxidase inhibitor VAS 2870 (VAS). MN = micronuclei, BNC = binucleated cells. * p ≤ 0.05 vs. 
Ang II treated sample (Mann-whitney U-test). 
To investigate the activation of NADPH oxidase, migration of the p47 subunit from 
cytosol to the membrane was monitored. A higher proportion of p47 was observed in 
the membrane after 1 hour of Ang II treatment. However, the presence of unspecific 
bands in the Western blot hindered us from quantification of the bands. Therefore, 
phosphorylation of p47 after Ang II treatment was assessed using 
immunoprecipitation. The results showed a higher phosphorylation of p47 after 1 and 
2 hours incubation with Ang II (Figure 18).  
Results 38 
IP: p47, WB: p-Ser
p47
0 30 60 120 240Ang II (min)  
0
1
2
3
0 30 60 120 240
F
o
ld
in
c
re
a
s
e
o
v
e
r
c
o
n
tr
o
l
Ang II (min)
**
4
 
Figure 18 Activation of NADPH oxidase in HK-2 cells investigated by phosphorylation of its p47 
subunit after the indicated duration of 200 nM Ang II treatment. 
In kidney, mostly two isoforms of Nox family called Nox2 and Nox4 are present. Nox2 
is the only member of Nox family which secrets superoxide to the outside of the cell 
membrane (101). Before, we showed that incubation of the cells with Ang II and 
superoxide dismutase is not able to reduce the genotoxic effect of Ang II, while 
TEMPOL which is cell membrane permeable reduces the effect. The fact that only 
cell permeable TEMPOL could prevent the effect of Ang II, was a hint for the 
involvement of Nox4. It is known that phosphorylation of Rac1 is necessary for 
activation of Nox2, but Nox4 does not need Rac1 for its activation. Rac1 is 
phosphorylated by PI3K to be activated. We inhibited PI3K with the two specific 
inhibitors wortmannin and LY-294002 to prevent Nox2 activation. As illustrated in 
Figure 19 none of these compounds prevented the induction of DNA damage by Ang 
II as measured in the comet assay. To ensure that the used concentration of 
wortmannin was enough to inhibit the activity of PI3K, the phosphorylation of Akt, 
another substrate of this enzyme was measured in western blot. The same 
concentration of wortmannin which was used in our genotoxicity tests completely 
hindered phosphorylation of Akt. 
Results 39 
0
1
2
3
4
5
D
N
A
 i
n
 t
a
il
(%
)
Ang II
- - 0.1 1wortmannin (µM)
- + + +
-
+
- - - -LY294002 (µM) 10
*
 
Ang II
- - 0.1 1wortmannin (µM)
- + + +
phosphorylated Akt
 
Figure 19 DNA damage measurement after 4 h treatment of HK-2 cells with 200 nM Ang II and 
the two PI3K inhibitors wortmannin and LY 294002. * p ≤ 0.05 vs. Ang II treated sample (Mann-
whitney U-test). The phosphorylation of Akt, a downstream substrate of PI3K, was assessed to 
ensure that the used concentration of the inhibitors were able to inhibit PI3K activity.  
We also inhibited Nox2 and Nox4 isoforms using siRNA strategy. The downregulation 
of Nox2 and Nox 4 was confirmed by RT-PCR and also in Western blot. The cells 
were then treated either with PBS as the negative control or with Ang II. The data 
represented in Figure 20 and Figure 21 show that the cells that were treated with 
Nox2-siRNA did not show any difference to the cells which served as the control. 
However, Nox4-siRNA downregulation hindered DNA damage formation induced by 
Ang II. 
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Figure 20 DNA damage measured by the micronucleus frequency test after 200 nM Ang II 
treatment for 4 h in HK-2 cells transfected with Nox2-siRNA. MN = micronuclei, BNC = 
binucleated cells. The success of siRNA transfection was confirmed by RT-PCR. * p ≤ 0.05 vs. 
Transfection buffer treated sample (Mann-whitney U-test). 
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Figure 21 DNA damage measured by the micronucleus frequency test after 200 nM Ang II 
treatment for 4 h in HK-2 cells transfected with Nox4-siRNA. MN = micronuclei, BNC = 
binucleated cells. The success of siRNA transfection was confirmed by RT-PCR. * p ≤ 0.05 vs. 
Transfection buffer treated sample (Mann-whitney U-test). 
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4.1.6 The effect of protein kinase C inhibition on the genotoxicity of Ang II 
One potential mechanism to induce NADPH oxidase activation is via protein kinase C 
(PKC). PKC goes through an auto-phosphorylation process when it is activated. 
PKC β II for example becomes phosphorylated at serine 660 when it is activated. 
With the aid of an antibody which recognizes different isoforms of PKC only when 
they are phosphorylated at carboxy terminal residues homologous to serine 660 of 
PKC β II, we checked if PKC is activated after Ang II treatment. Figure 22 illustrates 
our results from Western blot analysis, showing a higher activation of PKC after Ang 
II treatment. Exploring the role of PKC in the induction of DNA damage by Ang II, 
sphingosine and rottlerin, two specific inhibitors of PKC were used. Both, comet 
assay and micronucleus frequency test, showed a decrease in DNA damage after 
incubation of the cells with these inhibitors together with Ang II (Figure 23).  
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Figure 22 Western blot analysis of phosphorylation of protein kinase C after indicated period of 
200 nM Ang II treatment in HK-2 cells. Phosphorylation of PKC was assessed by an antibody 
against phospho- Ser 660 PKC. * p ≤ 0.05 vs. untreated sample (Mann-whitney U-test). 
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Figure 23 DNA damage measured with the comet assay after treatment of HK-2 cells for 4 h 
with 200 nM Ang II with or without co-incubation with the indicated concentrations of PKC 
inhibitors, sphingosine and rottlerin. MN = micronuclei, BNC = binucleated cells. * p ≤ 0.05 vs. 
Ang II treated sample (Mann-whitney U-test). 
 
4.1.7 Inhibition of phospholipases and their effects on Ang II-induced DNA 
damage  
Phospholipase D (PLD) produces phosphatidic acid which is short-lived and is 
converted to diacylglycerol (DAG) which in turn can activate PKC. PLD inhibition by 
1-butanol failed to impede Ang II-induced DNA damage in our cells (Figure 24).  
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Figure 24 DNA damage induced by 4 h treatment of HK-2 cells with 200 nM Ang II and the 
indicated concentrations of 1-butanol, a specific inhibitor of PLD.    
Involvement of phospholipase C (PLC) as the activator of PKC was investigated 
using the inhibitor U-73122, which successfully protected the cells against Ang II-
induced DNA damage (Figure 25), while U-73343, the inactive analogue of the 
inhibitor failed to show the similar effect at both tested concentrations. 
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Figure 25 Effect of the phospholipase C inhibitor U-73122 on the micronucleus formation 
induced by 4 h treatment of HK-2 cells with 200 nM Ang II.  The same concentrations of an 
inactive analog of phospholipase C inhibitor U-73343 was also investigated to confirm the 
specificity of the inhibitor. MN = micronuclei, BNC = binucleated cells. * p ≤ 0.05 vs. Ang II 
treated sample (Mann-whitney U-test). 
4.1.8 The effect of Gα-q/11 and Gβγ inhibition on Ang II-induced genotoxicity  
AT1R is a G-protein coupled receptor (GPCR). Gα-q/11 is coupled to AT1R which later 
binds to Gβγ and activates PLC. We used GP-2A, a competitive Gα-q inhibitor and 
gallein a Gβγ inhibitor to confirm that the signaling via AT1R and the subsequent 
pathway which involves G-proteins are responsible for the observed genotoxicity of 
Ang II. Inhibition of both G-protein types resulted in a decrease of Ang II-induced 
DNA damage to the control level (Figure 26). 
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Figure 26 DNA damage measured by the comet assay after 4 h treatment of HK-2 cells with 200 
nM Ang II with or without co-incubation with the indicated concentrations of the Gα-q G-protein 
inhibitor GP-2A or Gβγ inhibitor gallein . * p ≤ 0.05 vs. Ang II treated sample (Mann-whitney U-
test). 
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Also, the effect of Gαi/o inhibition on the genotoxicity of Ang II was investigated using 
pertussis toxin. The data presented in Figure 27 confirm the role of pertussis toxin 
sensitive Gαi/o subunits of G-proteins in genotoxicity of Ang II.  
0
2
3
1
D
N
A
 i
n
 t
a
il
(%
)
Ang II
- - 0.2 2PTX (ng/ml)
- + + +
* *
 
Figure 27 DNA damage measured by the comet assay after 4 h treatment of HK-2 cells with 200 
nM Ang II with or without co-incubation with the indicated concentrations of the Gαi/o G-protein 
inhibitor pertussis toxin. * p ≤ 0.05 vs. Ang II treated sample (Mann-whitney U-test). 
4.1.9 Involvement of calcium in Ang II-induced DNA damage 
Figure 28 illustrates a schematic representation of PKC activation by calcium. The 
involvement of calcium in the activation of PKC by Ang II was investigated. Ang II 
treatment resulted in calcium release which could be chelated by the calcium chelator 
BAPTA-AM (Figure 29). This effect of BAPTA-AM also prevented DNA damage 
induced by Ang II (Figure 30).  
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Figure 28 Schematic representation of PKC activation by PLC and involvement of calcium. PLC 
acts on PIP2 in the membrane and produces IP3 and DAG. DAG can directly activate PKC. IP3 
binds to its receptor on endoplasmic reticulum and causes release of calcium from ER calcium 
stores. The released calcium can activate PKC. 
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Figure 29 Calcium release in HK-2 cells in response to 200 nM Ang II treatment for 30 min, 
visualized with help of the fluorescent calcium binding dye Fluo-4. The released calcium can be 
chelated by BAPTA which also leads to decreased DNA damage induced by Ang II. 
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Figure 30 DNA damage measured in the comet assay after 4 h treatment of HK-2 cells with 200 
nM Ang II with or without co-incubation with the calcium chelator BAPTA-AM. * p ≤ 0.05 vs. Ang 
II treated sample (Mann-whitney U-test). 
To distinguish between the source of calcium which is necessary for the activation of 
PKC and the consequently observed DNA damage after Ang II treatment, a variety of 
compounds were used. First, thapsigargin was used to deplete the calcium stores of 
the cells. Thapsigargin is a plant derived compound which inhibits a class of enzymes 
known as sarco/endoplasmic reticulum Ca2+-ATPase. Inhibition of these enzymes 
blocks the ability of the cells to pump calcium into the sarcoplasmic and endoplasmic 
reticula which causes these stores to become depleted. We pre-treated our cells with 
thapsigargin for 30 min, followed by 4 hours of Ang II treatment. In this manner, 
Ang II failed to induce DNA damage in the comet assay. The number of micronuclei 
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was slightly increased after thapsigargin and Ang II treatment in comparison to the 
negative control, but this was significantly lower than the number of micronuclei 
induced by Ang II alone (Figure 31).  
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Figure 31 Induced micronuclei after 4 h treatment of HK-2 cells with 200 nM Ang II with or 
without 30 min pre-incubation with the calcium depletor thapsigargin. MN = micronuclei, BNC = 
binucleated cells. * p ≤ 0.05 vs. Ang II treated sample (Mann-whitney U-test). 
 
The calcium channels on the endoplasmic reticulum are IP3 receptor (IP3R)-
associated. Therefore, we used a blocker of these channels (2-APB) as well as an 
IP3R antagonist (TMB-8). Both of these compounds successfully reduced the 
damage by Ang II in the comet assay and in the micronucleus frequency test (Figure 
32 and Figure 33), confirming the role of endoplasmic calcium stores in the 
genotoxicity of Ang II.  
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Figure 32 Micronuclei formation in response to 200 nM Ang II and the ER calcium channel 
blocker 2-APB for 4 h in HK-2 cells. MN = micronuclei, BNC = binucleated cells. * p ≤ 0.05 vs. 
Ang II treated sample (Mann-whitney U-test). 
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Figure 33 Micronuclei formation in response to 200 nM Ang II and the IP3R antagonist TMB8 for 
4 h in HK-2 cells. MN = micronuclei, BNC = binucleated cells. * p ≤ 0.05 vs. Ang II treated 
sample (Mann-whitney U-test). 
 
In the next step, the potential role of extracellular calcium was investigated. For this 
purpose, the cells were washed 30 min. before the experiment and then calcium free 
medium was added to the flask. Treatment of the cells with Ang II in calcium free 
medium failed to induce damage assessed by comet assay and MN test (Figure 34).  
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Figure 34 Micronuclei formation in HK-2 cells in response to 4 h treatment with 200 nM Ang II in 
calcium free medium. MN = micronuclei, BNC = binucleated cells. * p ≤ 0.05 vs. Ang II treated 
sample in normal medium (Mann-whitney U-test). 
 
Furthermore, amlodipine, an inhibitor of membrane calcium channels impeded the 
genomic damage caused by Ang II (Figure 35). In summary, these results pointed to 
the role of extracellular calcium ions as well as intracellular calcium stores. 
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Figure 35 Micronuclei formation in HEK-293 cells in response to 4 h treatment with 200 nM Ang 
II and the indicated concentration of membrane calcium channel blocker amlodipine. MN = 
micronuclei, BNC = binucleated cells. * p ≤ 0.05 vs. Ang II treated sample (Mann-whitney U-test). 
 
To confirm that the observed effect of these compounds on genotoxicity is due to the 
intervention in calcium concentrations inside the cells, the cells were stained for 
calcium using Fluo-4 and then visualized under a confocal microscope. The pictures 
were quantified by measuring the average of the fluorescence intensity in 200 cells. 
Ang II treatment resulted in the increase of fluorescent intensity up to two fold of the 
negative control. This increase was absent when the cells were treated in calcium 
free medium or after treatment with Ang II and either of BAPTA-AM, thapsigargin, 
TMB8 and 2-APB. The results of the quantification are shown in Figure 36.  
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Figure 36 Quantification of calcium release in HK-2 cells, visualized by the fluorescent calcium 
binding dye Fluo-4 after 30 min. treatment with 200 nM Ang II and the indicated compounds to 
intervene calcium signaling. * p ≤ 0.05 vs. Ang II treated sample (Student’s t-test). 
 
4.2 Dopamine 
 
4.2.1 Evidence of dopamine-induced genotoxicity in vitro 
The genotoxicity of the neurotransmitter dopamine was investigated using the 
micronucleus frequency test in several cell lines of different tissue origin. The cell 
lines were selected from dopamine-responsive tissues. (A part of the results which 
are not presented here are included in reference (112)). While the human 
lymphoblastoid TK6 cells showed a significant response at 25 µM dopamine and 
higher, but not with the tested concentrations 6.25 and 12.5 µM, rat kidney NRK and 
rat pheochromocytoma PC12 cells exhibited clearly elevated micronucleus 
frequencies with all tested concentrations. The results of the micronucleus frequency 
test in NRK cells are depicted in Figure 37. PC12 cells revealed a more pronounced 
induction of micronuclei than TK6 and NRK cells. MDCK and LLC-PK1 cell lines did 
not show any increase in the number of micronuclei after treatment with different 
concentrations of dopamine (MDCK 6.25-100 µM, LLC-PK1 50-200 µM, data for 
LLC-PK1 cells not shown here).  
 
4.2.2 Evidence of dopamine-induced apoptosis 
Different concentrations of dopamine were used to investigate if this neurotransmitter 
can also induce apoptosis in vitro. We did not observe any induction of apoptosis with 
100 µM dopamine, while 300 µM of dopamine caused significantly elevated 
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apoptosis frequencies in TK6 and PC12 cells (Table 3). H2O2 was used as a positive 
control which induced a significant number of apoptotic cells in TK6 and NRK cells. 
The positive control could not be quantified in PC12 cells due to excess toxicity/cell 
fragmentation.   
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Figure 37 Dopamine-induced genotoxicity quantified by micronucleus frequency test in NRK 
cells after 4 h incubation with indicated concentrations of dopamine. MN = micronuclei, BNC = 
binucleated cells. * p ≤ 0.05 vs. untreated sample (Mann-Whitney U-test). 
 
Cell line Test substance 
 
Concentration (µM) % Apoptotic 
cells 
TK6  Control 
Dopamine 
 
H2O2 
0 
100 
300 
100 
1.3 ± 0.4 
2.2 ± 1.1 
4.5 ± 0.5*  
8.9 ± 3.6*  
NRK Control 
Dopamine 
 
H2O2 
0 
100 
300 
100 
0.7 ± 0.2 
0.9 ± 0.2 
0.9 ± 0.3 
13.9 ± 1.0*  
PC12 Control 
Dopamine 
 
0 
100 
300 
1.3 ± 0.1 
1.9 ± 0.6 
5.3 ± 0.6 * 
Table 3 Dopamine-induced apoptosis in vitro. Significance (p ≤ 0.05 in Mann-Whitney U-test 
versus the control of the same cell line) is indicated by an asterisk (*). 
Results 51 
4.2.3 Role of dopamine receptor D1 in the genotoxicity of dopamine 
PCR analysis confirmed the presence of D1 and D2 type receptors as well as of 
dopamine transporter (DAT) in PC12 cells (112). Therefore we decided to use these 
cells for experiments combining dopamine receptor antagonists and DAT inhibitors 
with dopamine. We investigated the role of D1R in the genotoxicity of dopamine. 
SCH 23390 was used as an antagonist of D1R in NRK and PC12 cells. In both cell 
lines (data from NRK cells are not shown) the antagonist reduced the genotoxic 
effect of dopamine (Figure 38).  
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Figure 38 Micronuclei formation in response to 4 h incubation with 100 µM dopamine together 
with D1R inhibitor SCH 23390. MN = micronuclei, BNC = binucleated cells. * p ≤ 0.05 vs. 
dopamine treated sample (Mann-Whitney U-test). 
 
We also questioned if signaling from D1R alone leads to a DNA damage response in 
the absence of dopamine. For this reason we used a potent agonist of D1R, 
SKF 38393 to see if activation of D1R can increase micronucleus formation in PC12 
cells. No increased formation of micronuclei was observed when the cells were 
treated with this agonist at concentrations of up to 120 µM (Figure 39).  
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Figure 39 Micronuclei induced by 4 h treatment with the indicated concentrations of the D1R 
agonist SKF 38393 in PC12 cells. MN = micronuclei, BNC = binucleated cells. 
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4.2.4 Role of dopamine receptor D2 in the genotoxicity of dopamine 
The D2 receptor antagonist sulpiride (Figure 40) reduced the genotoxic effect of 
dopamine significantly. The G-protein coupled receptor D2R is coupled with the Gαi/o 
protein, which is sensitive to the inhibitor pertussis toxin. This compound was applied 
to block the signaling from D2R in PC12 cells. Figure 41 shows that pertussis toxin 
significantly reduced the genotoxicity of dopamine in the micronucleus frequency test. 
These findings revealed a role for the D2 receptor as a mediator of dopamine-
induced genotoxicity.   
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Figure 40 Micronuclei formation after 4 h treatment of PC12 cells with 100 µM dopamine with or 
without co-incubation with the D2R antagonist, sulpiride. MN = micronuclei, BNC = binucleated 
cells. * p ≤ 0.05 vs. dopamine treated sample (Mann-Whitney U-test). 
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Figure 41 DNA damage measured by micronucleus frequency test after 4 h treatment of PC12 
cells with 100 µM dopamine with or without co-incubation with the indicated concentrations of 
the Gαi/o G-proteins inhibitor pertussis toxin (PTX). MN = micronuclei, BNC = binucleated cells. * 
p ≤ 0.05 vs. dopamine treated sample (Mann-Whitney U-test). 
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To investigate if activation of D2R signaling alone is enough to cause genotoxic 
damage even in the absence of dopamine, we stimulated D2R with quinpirole, a 
widely used D2R and D3R agonist. As illustrated in Figure 42, the indicated 
concentrations of quinpirole of up to 50 µM did not induce the formation of 
micronuclei. 
We performed Real-time analysis of DAT expression after quinpirole treatment to 
question if D2R activation with quinpirole in the concentrations which failed to induce 
micronucleus formation affects the DAT expression level. PC12 cells were treated 
with quinpirole, total RNA was extracted and cDNA was produced. Afterwards the 
expression of DAT was quantified (Figure 43). Our results show that the expression 
of DAT increased significantly after 2 and 4 hours. 
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Figure 42 Micronuclei induced by 4 h treatment of PC12 cells with the indicated concentrations 
of the D2R agonist quinpirole. MN = micronuclei, BNC = binucleated cells. 
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Figure 43 Expression of dopamine transporter after indicated periods of treatment with  50 µM 
D2R agonist quinpirole quantified by q-PCR. * p ≤ 0.05 vs. untreated sample (Mann-Whitney U-
test). 
 
4.2.5 Role of DAT in the genotoxicity of dopamine 
We applied two different approaches to check for the role of DAT in dopamine-
induced genotoxicity. First we used pharmacological inhibitors of DAT in combination 
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with dopamine in PC12 cells. GBR 12909 and nomifensine were used to inhibit DAT 
in our cell line. The results show that inhibition of DAT with either of these two 
inhibitors resulted in the formation of a lower number of micronuclei in comparison to 
the dopamine treated sample (Figure 44).  
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Figure 44 Prevention of MN formation induced by 4 h treatment of PC12 cells with 100 µM 
dopamine after co-incubation with the two DAT inhibitors nomifensine and GBR 12909. MN = 
micronuclei, BNC = binucleated cells. * p ≤ 0.05 vs. dopamine treated sample (Mann-Whitney U-
test). 
As mentioned before (4.2.1), the MDCK cell line did not show any DNA damage 
response when treated with different concentration of dopamine. Therefore, we used 
MDCK-DAT cells which were transfected with the human DAT gene, to investigate if 
the presence of the DAT gene can change the response of MDCK cells to dopamine. 
The activity of the transfected gene was confirmed elsewhere (34). As depicted in 
Figure 45, MDCK-DAT cells which where able to take up dopamine showed a dose-
dependent micronucleus formation response whereas MDCK cells failed to show any 
DNA damage response. 
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Figure 45 Dopamine-induced genotoxicity quantified by the micronucleus frequency test in 
MDCK and MDCK-DAT cells after 4 h incubation with the indicated dopamine concentrations. 
MN cells = micronucleated cells, BNC = binucleated cells. * p ≤ 0.05 vs. untreated sample of the 
same cell line (Mann-Whitney U-test). 
 
4.2.6 Genotoxicity of dopamine is mediated via ROS production 
Since dopamine has been reported to exert oxidative stress in mammalian cells, we 
tested whether a known antioxidant could reduce the micronucleus formation after 
dopamine treatment (Figure 46). The superoxide radical scavenger TEMPOL as well 
as the hydroxyl radical scavenger dimethylthiourea (DMTU) were in fact able to 
reduce micronucleus induction in PC12 cells significantly, but not completely.  
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Figure 46 Effects of 4 h incubation with 50 µM of the superoxide scavenger TEMPOL or 10 mM 
of the hydroxyl radical scavenger DMTU on the micronucleus induction by 100 µM dopamine. 
MN cells = micronucleated cells, BNC = binucleated cells. * p ≤ 0.05 vs. dopamine treated 
sample (Mann-Whitney U-test). 
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4.2.7 Monoamine oxidase as a potential source of ROS formation 
After uptake in cells, dopamine is either metabolized by the enzyme monoamine 
oxidase (MAO), other oxidizing enzymes or undergoes autoxidation. To distinguish 
whether any of these options is relevant in the genotoxicity of dopamine, we inhibited 
MAO with 50 µM of the MAO inhibitor trans-2-phenylcyclopropylamine hydrochloride 
(PCPA) and also with 1 µM of the MAO B specific inhibitor Ro 16-6491 in PC12 cells 
(Figure 47 and Figure 48 respectively). Both compounds reduced the number of 
micronuclei induced by dopamine, indicating that oxidation of dopamine by MAO is 
likely to play a role in the genotoxicity of dopamine. Once dopamine is metabolized 
by MAO, semiquinones, quinones and ROS are produced, which all are potentially 
able to damage cellular DNA. We used another substrate of MAO, 1-
phenylethylamine (PEA) with a similar structure to dopamine, which can be 
metabolized to ROS but not to semiquinones or quinones (Figure 49). PEA induced 
micronuclei in PC12 cells, though not as many as dopamine, implying that ROS 
formation plays a role in dopamine genotoxicity, but semiquione- and quinone-
formation may also contribute.  
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Figure 47 Micronucleus induction after 4 h treatment of PC12 cells with 100 µM dopamine with 
or without co-incubation with 50 µM of the monoamine oxidase inhibitor trans-2-
phenylcyclopropylamine hydrochloride (PCPA).  MN cells = micronucleated cells, BNC = 
binucleated cells. * p ≤ 0.05 vs. dopamine treated sample (Mann-Whitney U-test). 
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Figure 48 Micronucleus induction after 4 h treatment of PC12 cells with 100 µM dopamine with 
or without co-incubation with 1 µM of the MAO B specific inhibitor Ro 16-6491.  MN cells = 
micronucleated cells, BNC = binucleated cells. * p ≤ 0.05 vs. dopamine treated sample (Mann-
Whitney U-test). 
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Figure 49 Micronucleus induction by the indicated concentration of monoamine oxidase 
substrate 1-phenylethylamine (PEA) for 4 h in PC12 cells. MN cells = micronucleated cells, BNC 
= binucleated cells. * p ≤ 0.05 vs. untreated sample (Mann-Whitney U-test). 
 
4.2.8 Potential antioxidant capacity of deployed inhibitors  
To ensure the absence of intrinsic antioxidant capacities of the inhibitors used to 
study the signal transduction pathways, which would give artefactual results, we 
tested the receptor antagonists and transporter inhibitors for their own potential 
antioxidative capacity (Figure 50). The formation of strand breaks as well as alkali 
labile sites can be monitored in the comet assay. In the combination with hydrogen 
peroxide, which is known to cause DNA-damage in the comet assay via oxidative 
stress, SCH 23390, sulpiride and nomifensine at the concentration used in the 
micronucleus test (30 µM for nomifensine) did not reduce the effect of hydrogen 
peroxide in the comet assay, while the positive control N-acetylcysteine (NAC), a 
precursor of glutathione which scavenges hydrogen peroxide, almost completely 
prevented comet formation. Interestingly, the DAT inhibitor GBR 12909 showed some 
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protective activity and thus revealed antioxidant capacity. A higher concentration of 
nomifensine (60 µM) also revealed a non-significant intrinsic antioxidant capacity. 
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Figure 50 : Influence of the D1R antagonist SCH 23390, D2R antagonist sulpiride, the dopamine 
transporter inhibitors GBR 12909 and nomifensine and of the antioxidant N-acetylcysteine 
(NAC) (served as the positive control) on 30 min hydrogen peroxide (H2O2) induced DNA-
damage in HL-60 cells detected in the comet-assay. * p ≤ 0.05 vs. H2O2 treated sample (Mann-
Whitney U-test). 
 
4.2.9 Role of PI3K and ERK1/2 in the genotoxicity of dopamine 
The role of PI3K and ERK1/2 inhibition was investigated, since it has been reported 
that activation of D2R can activate PI3K and ERK1/2 (17). A number of studies have 
revealed that the activity of these kinases can ultimately affect redistribution of DAT 
from the cytosol to the membrane. To elucidate the role of these kinases in the 
pathway of genotoxicity of dopamine, we inhibited PI3K and ERK1/2 and evaluated 
the dopamine-induced micronucleus formation in PC12 cells. PI3K was inhibited 
using the specific inhibitor wortmannin. Concentrations of 0.1 and 1 µM were able to 
decrease the number of dopamine-induced micronuclei (Figure 51). 
Activation of ERK1/2 was inhibited using an ERK1/2 activation inhibitor peptide which 
was first developed by Kelemen et al (59). This membrane permeable peptide 
selectively binds to ERK and prevents its interaction with MEK (MAP kinase kinase). 
The inhibitory peptide was able to impede the damage to the genetic material which 
was induced by dopamine alone (Figure 52). Thus, PI3K and ERK1/2 both contribute 
to the genotoxicity of dopamine. 
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Figure 51 Micronucleus formation after treatment of PC12 cells with 100 µM dopamine for 4 h, 
with or without co-incubation with the indicated concentrations of the PI3K inhibitor 
wortmannin. MN cells = micronucleated cells, BNC = binucleated cells. * p ≤ 0.05 vs. dopamine 
treated sample (Mann-Whitney U-test). 
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Figure 52 Micronucleus formation after treatment of PC12 cells with 100 µM dopamine for 4 h, 
with or without co-incubation with the indicated concentrations of an ERK activation inhibitor 
peptide. MN cells = micronucleated cells, BNC = binucleated cells. * p ≤ 0.05 vs. dopamine 
treated sample (Mann-Whitney U-test). 
 
4.2.10 Immunocytochemical staining of DAT 
In order to investigate the effect of dopamine on the localization of DAT and the role 
of D2R in this process, we stained the DAT in MDCK-DAT cells which were treated 
with dopamine with or without pre-incubation with the D2R antagonist sulpiride. 
Treatment of MDCK-DAT cells with 100 µM of dopamine for 5 and 15 min. (Figure 
53b and Figure 53c respectively) led to an increase of DAT migration from the cytosol 
to the membrane in comparison to untreated cells (Figure 53a), where DAT was 
more distributed throughout the cytosol. Pre-treatment of the cells with 10 µM of 
sulpiride for 10 min. prevented this migration and resulted in an equal distribution of 
DAT in the cytosol and membrane regions (Figure 53d and Figure 53e). Figure 53f 
shows that treatment with 50 µM of the D2R agonist quinpirole for 15 min. resulted in 
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an increased localization of DAT in the cell membrane. The manner of quantification 
of DAT distribution between cytosol and membrane is explained in the materials and 
method section (3.19) (Figure 6) and the results of this quantification are illustrated in 
Figure 54. 
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Figure 53 Immunocytochemical staining of MDCK-DAT cells for the localization of the 
dopamine transporter protein (DAT). (A) untreated cells, (B) dopamine 100 µM for 5 min, (C) 
dopamine 100 µM for 15 min, (D) 10 min. incubation with 10 µM of sulpiride followed by 5 min. 
incubation with 100 µM of dopamine, (E) 10 min. incubation with 10 µM of sulpiride followed by 
15 min. incubation with 100 µM of dopamine, (F) quinpirole 50 µM for 15 min.  
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Figure 54 Quantification of the ratio of DAT localization in membrane and cytosol after 
treatment of the cells with 100 µM of dopamine with or without pre-incubation with 10 µM of the 
D2R antagonist sulpiride or after treatment with 50 µM of the D2R agonist quinpirole.  * p ≤ 0.05 
vs. untreated sample, † p ≤ 0.05 vs. 5-minute dopamine treated sample, ◊ p ≤ 0.05 vs. 15-minute 
dopamine treated sample (Student’s t-test). 
 
4.2.11 The effect of L-Dopa therapy in Parkinson’s disease patients  
To check if our results in vitro are of any relevance in vivo, we looked for a 
therapeutic model which results in higher concentration of dopamine in vivo. High 
dose L-Dopa therapy of Parkinson’s disease patients provides a suitable model due 
to conversion of L-Dopa to dopamine also in the circulation system. We looked for 
the micronucleus formation in the peripheral blood lymphocytes of the L-Dopa treated 
patients and also of the control group. Demographic and clinical data of the subjects 
enrolled in this study are presented in Table 1 and Table 2. Figure 55 shows that no 
difference in the number of micronuclei between the patient and the control group 
was found. Micronucleus frequency is known to be influenced by gender with higher 
observed micronucleus formation in females. To account for a potential influence of 
gender, we added eight male individuals not suffering from PD to the micronucleus 
analysis of the control group. Together with these, the micronucleus frequency of the 
18 patients (18.8 ± 7.1 micronucleated/1000 binucleated cells, 12 male/6 female, 
71.1 ± 3.2 years) could then also be compared with an overall control group of 18 
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individuals (14.6 ± 8.3 micronucleated/1000 binucleated cells, 9 male/9 female, 63.4 
± 10.7 years). Still, no significant difference between the groups was found. 
A comparison of the micronucleus values for patients receiving dopamine agonists 
(nine patients) and those who did not (nine patients) revealed slightly elevated values 
for patients with additional dopamine agonist therapy (Figure 56). A positive 
correlation of L-Dopa dose with micronuclei was found for the patients receiving 
dopamine agonists (Figure 57b), while micronucleus frequency showed no 
correlation with dose of L-Dopa in the patients without additional dopamine agonist 
therapy (Figure 57a). 
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Figure 55 Micronuclei frequency in peripheral blood lymphocytes of healthy individuals 
(control) and Parkinson’s disease patients after chronic L-Dopa treatment. 
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Figure 56 Micronuclei frequency in peripheral blood lymphocytes of Parkinson’s disease 
patients after chronic L-Dopa treatment with or without additional dopamine agonist treatment. 
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Figure 57 Correlation of micronucleus formation and the daily dose of L-Dopa in patients 
without (a) or with (b) additional dopamine agonist therapy. 
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5 Discussion 
 
The damaging effects of ROS on biological molecules are well described. ROS are 
produced by both exogenous and endogenous sources. Potential exogenous 
sources comprise of metal ions, radiation, chlorinated compounds, barbiturates, 
phorbol esters and others (62). Some sources of endogenous ROS are oxidative 
phosphorylation, cytochrome P450 mediated metabolism, peroxisomes, inflammatory 
cell activation and ROS producing enzymes. In this work we focused on endogenous 
ROS which are produced by the ROS generating enzyme NADPH oxidase after Ang 
II treatment and by oxidative metabolism of dopamine by monoamine oxidase which 
leads to the formation of H2O2 as a by-product.  
Under physiological conditions, the amount of ROS which occurs in the body is easily 
scavenged by components of the antioxidant defense system like antioxidant 
enzymes (superoxide dismutase, catalase, glutathione peroxidase), endogenous 
antioxidants (glutathione) or exogenous antioxidants from food intake (vitamins, 
polyphenols, etc.). When the redox balance in the body is disturbed in favour of pro-
oxidants due to a pathological condition, a demand for higher activation of the 
antioxidative defense system occurs. In this case, the success of the defense system 
depends on the amount of produced ROS, the efficacy of antioxidant enzymes and 
nutritional habits of the individual. 
Accumulating evidence indicates a role of ROS in the pathology of cardiovascular 
diseases. The renin-angiotensin-aldosterone system (RAAS) is an important part of 
physiological and pathological responses of the cardiovascular system. The 
biologically active hormone of this system, Ang II, is not only responsible for 
vasoconstriction and blood regulation but is also implicated in inflammation, 
endothelial dysfunction, atherosclerosis, hypertension and congestive heart failure 
(76). Some of these effects of Ang II are mediated via production of ROS generated 
by membrane bound nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
localized in the vascular walls (46, 119).  
Our group has shown that DNA damage was induced by Ang II in cell lines derived 
from kidney (105) as well as in perfused isolated mouse kidneys (104). The damage 
included single and double strand breaks, chromosomal aberrations, abasic sites and 
8-oxodG base modifications. These effects of Ang II were mediated via its AT1 
receptor. The purpose of this study was to scrutinize the pathway involved in the 
observed genotoxicity of Ang II. Here we confirmed the genotoxicity of Ang II in two 
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other kidney cell lines of human origin, HEK-293 and HK-2 cells. In HEK-293 cells, 
Ang II caused significant DNA damage after 1h of incubation. Using the superoxide 
specific dye dihydroethidium we showed that Ang II treatment led to superoxide anion 
production which was abolished by the membrane permeable superoxide dismutase 
(SOD) mimetic TEMPOL. The DNA damage caused by Ang II was also prevented by 
TEMPOL but not by addition of SOD itself. This led us to the conclusion that the 
produced ROS were responsible for the observed DNA damage and that SOD was 
not able to reduce damage due to its inability to cross the cell membrane. 
Combination of Ang II with catalase also prevented DNA damage to some extent. 
There is a report about the ability of cells to take up catalase. The fact that pre-
incubation with catalase more efficiently prevented Ang II-induced damage than co-
incubation is in agreement with this report. Pig kidney, LLC-PK1 cells, start showing 
DNA damage measured by comet assay after 15 minutes of Ang II treatment. 
Catalase was not able to protect the cells at this time point. With increased incubation 
time, catalase was probably taken up by the cells and exhibited its antioxidant 
capacity inside the cells where the ROS are produced (unpublished data). Because 
Ang II is reported to be able to induce the formation of 8-oxodG base modification 
which is formed by the hydroxyl radical, we also investigated if the hydroxyl radical 
scavenger DMTU can reduce the DNA damage induced by Ang II. DMTU decreased 
the effect of Ang II only to some extent. This can be either explained by the fact that 
the hydroxyl radical is very active and its migration distance in the cells is very limited 
which confines its interactions to the adjacent molecules or most of the damage 
induced by Ang II is formed by superoxide radicals and H2O2 instead of the hydroxyl 
radical.  
The quest for finding the source of ROS formation led us to NADPH oxidase which is 
also expressed in kidney cells. We found upregulation and phosphorylation of the 
p47 subunit of NADPH oxidase after Ang II treatment. Using two inhibitors we 
showed that inhibition of NADPH oxidase completely prevented DNA damage by Ang 
II treatment. Three homologs of the gp91phox subunit of NADPH oxidase, Nox1, 
Nox2 and Nox4, are expressed in the kidney (40). Nox4 which has 35 % identity to 
Nox2 was initially characterized as kidney NADPH oxidase (42) and most probably is 
located on intracellular membranes (72). To distinguish whether only one or both of 
these isoforms are involved in the genotoxicity of Ang II, we tried to differentiate 
between Nox2 and Nox4 action. To the best of our knowledge, no pharmacological 
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isoform-specific inhibitor of Nox family has been developed so far (73). Using siRNAs, 
only inhibition of Nox4, but not of Nox2, abolished the effect. Except for Nox2, all 
other members of the Nox family release their superoxide product inside the cell. The 
results from our siRNA transfection and involvement of Nox4 explain the inability of 
SOD enzyme to prevent Ang II-induced DNA damage although the same 
concentration successfully protects the cells against the Nox2 activator PMA. In 
addition to this, we did not observe any reduction of the Ang II-induced genomic 
damage after inhibition of PI3K. PI3K is responsible for the phosphorylation of Rac1, 
which is necessary for activation of Nox2 (1) whereas at least in epithelial cells Rac1 
is not required for activation of Nox4 (72). In agreement to our results, using Nox4 
knockout mice, it has been shown that Nox4-mediated oxidative stress leads to 
neuronal damage and apoptosis. The same effect was not observed in mice with 
deficiency in Nox1 or Nox2 genes (63). In contrary to this and also to our results, 
recently it has been reported that Ang II induces superoxide anion production in a 
Nox2-dependent manner in a cell line with properties of macula densa (40). However, 
the mechanism of induction of superoxide formation may differ in cell lines of different 
origins.  
In the next step we looked for the role of PKC as a potential kinase which can 
phosphorylate p47 resulting in the activation of NADPH oxidase. The activation of 
PKC was confirmed by assessing its phosphorylation after Ang II treatment. Further 
investigation showed that inhibition of PKC hinders Ang II from damaging the cells. 
PKC itself can be activated by products of phospholipases. We inhibited PLC and 
PLD and looked for DNA damage induced by Ang II.  
Ang II can activate PLD resulting in hydrolysis of phosphatidylcholine (PC) to choline 
and phosphatidic acid (PA). PA is rapidly converted to diacylglycerol (DAG). DAG 
can ultimately activate PKC. No effect on the genotoxicity of Ang II after PLD 
inhibition was observed. We also inhibited PLC which is activated via stimulation of 
AT1R. Activation of PLC results in the production of inositol-1,4,5-triphosphate (IP3) 
and DAG. IP3 binds to its receptor at endoplasmic reticulum (ER), opening a channel 
which allows calcium efflux into the cytoplasm. Both calcium and DAG are potential 
activators of PKC. A specific inhibitor of PLC could almost completely abrogate the 
DNA damage caused by Ang II whereas the inactive isoform of the same inhibitor 
failed to show any inhibitory effect. According to these results we conclude that PLD 
is not involved in the pathway of Ang II-induced genomic damage but PLC is.  
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The ER calcium channel blocker 2-APB and the IP3 receptor antagonist TMB8, as 
well as the calcium store depletory compound thapsigargin hindered the genotoxicity 
induced by Ang II, which clearly shows the role of ER calcium signaling in this 
pathway. We also observed that incubation of the cells with Ang II together with the 
calcium chelator BAPTA-AM, the membrane calcium channel blocker amlodipine and 
also treatment of the cells with Ang II in a calcium free medium protected the cells 
against the damaging effect of Ang II. The latter results point to requirement of 
extracellular calcium as mediator of Ang II genotoxicity. Using fluorescence 
microscopy, we demonstrated that all the above mentioned interferences also lead to 
decreased calcium release by the cells. Involvement of both intra as well as 
extracellular calcium sources in the genotoxicity of Ang II is probably explained by the 
role of STIM1 as a signaling molecule which may act to amplify and augment the 
calcium signal (99). In an ongoing experiment, we transfected the HEK-293 cells with 
wild type and mutant gene of STIM1 to check this hypothesis. 
As mentioned above, PLC is activated by AT1R stimulation. AT1R is a GPCR which 
has been shown to be capable of coupling to various α-subunits (Gq, Gq/11, and Gi/o) 
(57, 91) as well as Gβγ complexes (76, 114). In line with previous findings (105) the 
AT1R antagonist candesartan reduced the genotoxicity of Ang II in HK-2 cells almost 
to the control level which confirms that the genotoxicity of Ang II is mediated via 
AT1R signaling. Supporting results came from inhibition of Gαq/11, Gαi/o and Gβγ. In all 
cases, inhibition of G-protein signaling abrogated the damage caused by Ang II.  
In conclusion, we show here that Ang II is able to induce genomic damage in cell 
lines of kidney origin. The observed damage is associated with production of ROS. A 
decrease in Ang II-induced DNA damage was observed after inhibition of G-proteins, 
PLC, PKC and NADPH oxidase and interfering with intra- as well as extracellular 
calcium signaling. This leads to the the following current model of signaling in Ang II-
induced DNA damage (Figure 58): binding of Ang II to the AT1 receptor activates 
PLC via stimulation of G-proteins, resulting in activation of PKC in a calcium 
dependent manner which in turn, activates NADPH oxidase. NADPH oxidase with 
involvement of its Nox4 subunit then produces ROS which cause DNA damage. 
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Figure 58 Model of signaling in Ang II-induced DNA damage. Binding of Ang II to the AT1 
receptor activates PLC via stimulation of G-proteins, resulting in activation of PKC in a calcium 
dependent manner which in turn, activates NADPH oxidase. NADPH oxidase with involvement 
of its Nox4 subunit then produces reactive oxygen species which cause DNA damage. Ang II = 
angiotensin II, AT1R = angiotensin type 1 receptor, Gα/q11 = G protein subunits Gα/q11, PLC = 
phospholipase C, IP3 = Inositol triphosphate, ER = endoplasmic reticulum, PKC = protein 
kinase C, ROS = reactive oxygen species. 
 
A large body of evidence links the production of ROS, subsequent oxidative stress 
and damage to biomolecules to the pathogenesis of age-related and chronic 
diseases (51, 62, 79, 97). It has been hypothesized that increased generation of 
ROS, elevated levels of oxidized DNA lesions or lower activity of host defense 
mechanisms is a driving force in the development of cancer in aged individuals (24). 
Some reports have shown that the repair activity decreases in higher age which can 
be associated with the accumulation of oxidatively damaged DNA and increased 
cancer risk. The link between the activity of the repair enzyme Ogg1 which repairs 8-
oxodG and cancer is plausible because case-control studies have shown that groups 
with low repair capacity had a higher odds ratio for different kinds of cancer (41, 95-
96). 
The presence of increased oxidative stress and oxidative damage in 
neurodegenerative diseases has been well characterized in a large number of 
publications (22, 31, 44, 71, 81). Particularly, the nervous system is very sensitive to 
oxidative stress because of the high content of polyunsaturated fatty acids, its high 
oxygen consumption rate (brain for example accounts for 20-25 % of the total body 
oxygen consumption, but for less than 2 % of the body weight)  and relatively fewer 
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antioxidant pathways (5, 15, 48). Catecholamines are an important source of ROS 
production in the CNS (16). For example, metabolism of dopamine, serotonin and 
norepinephrine by monoamine oxidase results in the production of H2O2 (23).   
L-Dopa therapy has been the first line treatment for Parkinson’s disease (PD) in the 
last three decades. PD is a neurodegenerative syndrome which together with 
Alzheimer’s disease accounts for the large number of neurodegenerative disease 
cases. The disease is characterized clinically by resting tremors, bradykinesia, 
muscular rigidity and postural instability. The clinical course of PD progresses over 
several years. Most of the clinical symptoms are secondary to the degeneration of 
dopaminergic neurons in the pars compacta of the substantia nigra. The surviving 
neurons often contain cytoplasmic inclusions that consist of fatty acids, 
polysaccharides, proteins and sphingomyelin (16). Beside sporadic cases, genetic 
predisposition may also increase the risk of PD. Mutation in genes which encode for 
α-synuclein, ubiquitin carboxyl-terminal hydrolase L1 and parkin are among the risk 
factors for PD (48). A number of environmental factors such as metals, foods, 
pesticides, head injuries and infections have been evaluated for their contribution in 
PD susceptibility and in recent years several interactions between environmental 
agents and genetic polymorphisms of metabolic enzymes have been observed (25). 
Smoking and caffeine for example are consistently reported to be associated dose-
dependently with risk of PD. The risk of the disease is also increasing with higher age 
and male gender (48).   
Several lines of evidence point to a role of oxidative stress in the pathology of PD. 
For example, lipid peroxidation is significantly higher in the brain of PD patients (30). 
But interestingly, despite an abundant evidence for an involvement of oxidative insult 
at early stages of PD, interventions like administration of one or a few antioxidants 
have been, at best, modestly successful in clinical trials (69). It is hypothesized that 
the complexity of ROS metabolism accounts for the failure of these interventions, 
which demands more integrated approaches which not only enrich the exogenous 
antioxidants but also upregulate the complex endogenous antioxidant defence 
system (48). 
The concentration of dopamine in the plasma (86) and also in the lymphocytes (102) 
of PD patients correlates significantly with the administered dose of L-Dopa. The 
suitability of lymphocytes as a peripheral marker of the central neuronal deficits in PD 
has been shown (4, 86). Decreased intracellular dopamine content has been 
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observed in the peripheral blood lymphocytes of early PD patients. Also, patients 
receiving L-Dopa have been found to have high dopamine levels in their lymphocytes 
(18). In the attempt to identify the potential effect of L-Dopa therapy on peripheral 
blood lymphocytes of PD patients, we recruited a group of PD patients and their life 
partners as the control subjects. Analysis of micronuclei frequency showed no 
significant difference in the number of micronuclei between patients and a control 
group. Females are known to have higher frequencies of micronuclei in their 
lymphocytes than males (36). The gender distribution was unequal between the 
groups in our study with more females in the control group because they were life 
partners of the male PD patients. For this reason we included data from six more 
male individuals to the control group but still did not observe any significant difference 
to the patient group. We also investigated the correlation between the micronucleus 
frequency and administered dose of L-Dopa in patients which received a dopamine 
agonist in addition to L-Dopa therapy. While no correlation was observed between 
micronucleus frequency and the L-Dopa dose in patients which were under L-Dopa 
therapy alone, the patients who received dopamine agonists in combination with L-
Dopa showed an increased number of micronuclei with higher doses of administered 
L-Dopa. The effect of dopamine receptor signaling on dopamine-induced genomic 
damage will be discussed later. In the same study we reported an elevated amount of 
8-oxodG formation, an important indication of oxidative stress, in lymphocytes of PD 
patients in comparison to the control group (92) which is in line with some post-
mortem studies in brains of PD subjects (2, 87). The fact that despite observed 
elevated levels of oxidative stress we did not see any increase in the micronucleus 
formation can be explained by the inherent antioxidant capacity of L-Dopa in a cell 
free system (92).  
In vitro we have confirmed the genotoxicity of dopamine in several cell lines of 
different tissue origin. We observed an increased number of micronuclei after 
dopamine treatment in rat epidermal kidney, NRK cell line with properties of proximal 
tubular cells, in rat pheochromocytoma PC12 cells and in the human B-
lymphoblastoid cells, TK6 (112). We did not observe any genotoxicity of dopamine in 
the epithelial porcine kidney cell line LLC-PK1 or the dog kidney MDCK cells with 
properties of distal tubules . Reduction of cell proliferation assessed by cytochalasin-
B block proliferation index was observed in TK6 and NRK cells and higher 
concentrations of dopamine caused apoptosis in TK6 and PC12 cells. PC12 cells 
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which express dopamine receptors and the transporter (112) showed a more 
pronounced genotoxic response in comparison to NRK and TK6 cells, which made 
them suitable for the following experiments. 
An early report suggested that the genotoxcity of dopamine is related to the 
generation of ROS, namely superoxide anion, hydrogen peroxide, singlet oxygen and 
hydroxyl radicals as a results of dopamine oxidation because they observed a 
reduction of DNA strand breaks after combination of dopamine with antioxidants, 
DMTU and SOD (80). In agreement to this, we also found a reduction in the 
dopamine-induced number of micronuclei in PC12 cells after treatment with 
dopamine and the radical scavengers TEMPOL and DMTU. This is in line with other 
reports, which demonstrated that the oxidation of dopamine via enzymatic pathways 
(for example by MAO) as well as autoxidation leads to the production of ROS (10, 16). 
We also demonstrated the release of H2O2 by PC12 cells into the culture medium 
after dopamine treatment. Our results using two different MAO inhibitors and 
dopamine in the micronucleus frequency test provide evidence that ROS production 
after MAO-dependent oxidation of dopamine plays the major role in the genotoxicity 
of dopamine, although autoxidation may add to this. MAO deaminates dopamine in 
the cytoplasm and produces H2O2 as by-product. H2O2 might damage the biological 
macromolecules of the cell. In the presence of ferrous ions, H2O2 is reduced to the 
highly reactive hydroxyl radicals through the Fenton reaction (8), which can attack 
nucleic acids, lipids and proteins in the cells directly or are converted to other radicals 
which all are potentially capable of damaging DNA as well as other biomolecules. 
The hydroxyl radical produces the altered DNA base 8-oxodG, which is an important 
biomarker for oxidative stress (75) and also the most abundant oxidative DNA lesion 
(20). Recently our group has shown in mass spectrometry measurements that 
treatment of PC12 cells with dopamine leads to a significant increase in 8-oxodG 
levels (34). These elevated levels of 8-oxodG were prevented when the MAO 
inhibitor PCPA was used in combination with dopamine, showing that dopamine-
induced 8-oxodG formation in this cell line is MAO dependent. Due to base 
mispairing, 8-oxodG can lead to G:C to T:A transversions after replication, 
representing point mutations (20, 37). Prevention of 8-oxodG formation is so vital for 
the cells that even phylogenetically ancient organisms such as Escherichia coli 
contain the MutT enzyme, which has 8-oxodGTPase activity responsible for the 
removal of 8-oxodGTP from the nucleotide pool (78).  
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PEA has a structure similar to dopamine with the exception of two hydroxyl groups 
lacking in the phenyl ring. This difference in structure hinders PEA from producing 
quinones and semiquinones after being deaminated by MAO, but not from production 
of H2O2 (32). PEA was able to induce micronucleus formation in PC12 cells, 
suggesting that the genotoxicity of dopamine may be due to the production of ROS. 
Since the effect of PEA was not as high as that of dopamine, formation of quinones 
and semiquinones may also be involved. Also it should be considered that PEA may 
not have the same affinity to dopamine receptors and the transporter as dopamine 
does (see below).  
In addition, we found a reduction of the genotoxicity of dopamine after co-treatment 
of the cells with dopamine together with D1R or D2R antagonists (SCH 23390 and 
sulpiride respectively). When used in high concentration, SCH 23390 is reported to 
have affinity to D2R as well (39). Unfortunately we could not find a more specific 
antagonist which exclusively affect the D1R. The use of siRNA down-regulation 
strategy or a D1R knock out cell line may be helpful to reveal the role of D1R in this 
pathway. Furthermore, some common molecular mechanism of D1R and D2R like 
activation of protein kinase B adds another level of complexity (9).  
Confirming the involvement of D2R signaling in dopamine-induced DNA damage, a 
combination of pertussis toxin with dopamine treatment was performed which 
reduced the dopamine-mediated micronucleus formation. Pertussis toxin inhibits the 
Gαi/o-coupled D2, D3, and D4 receptors (90), hence confirming the role of D2 like 
receptors in the dopamine-induced increase of micronuclei formation. In contrast, the 
D2 like receptor agonist quinpirole was not capable of inducing any genotoxic 
response in the absence of dopamine, which indicate that D2R signaling itself is not 
genotoxic, but is involved in the dopamine-induced genotoxicity. The inability of 
quinpirole to induce micronucleus formation cannot be attributed to low concentration 
of the compound because the same concentration was able to induce DAT migration 
to the membrane and also to upregulate DAT mRNA in Real-time PCR experiments.      
Treatment of the cells with dopamine and either of two DAT inhibitors GBR 12909 
and nomifensine also hindered the genotoxic effect of dopamine. Since dopamine is 
taken up into the cell via DAT, this would be in line with the idea that genotoxicity of 
dopamine occurs upon entry into the cell and subsequent oxidation inside the cell. 
Confirming results came from the gentoxicity assay in MDCK cells. MDCK-DAT cells 
which were transfected with human DAT (49) but not untransfected MDCK cells were 
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able to take up dopamine which was added to their medium (34) and then form 
micronuclei. This strong evidence of the role of DAT in dopamine-induced DNA 
damage is in line with our results from pharmacological inhibition of DAT using GBR 
12909 and nomifensine. 
The expression of D2R and DAT in axonal terminals is an anatomical hint for a 
potential interaction between these two proteins (52). Indications are that D2 
antagonists decrease the half life of the DAT protein in responsive brain tissues (21, 
61). Among neurotransmitters, transporter internalization and trafficking are common 
mechanisms of rapid regulation of transporter function. For example, it has been 
reported that PKC is involved in activation and cell surface expression of serotonin 
transporter (11, 100). Many other reports provide evidence about the role of kinases 
in the regulation of DAT (12, 65, 83, 118). Activation of PKC is reported to decrease 
the Vmax of DAT with no change in the affinity of the transporter for dopamine (28) 
and also to redistribute the localization of DAT from cell membrane to the cytosol (67, 
83). On the other hand PI3K and MAPK are reported to promote cell surface 
expression of DAT and therefore enhance dopamine uptake (19, 83). It has been 
suggested by others that stimulation of D2R leads to the activation of ERK and PI3K 
in a pertussis toxin sensitive manner (17). The latter implies the contribution of Gαi/o 
proteins which are coupled to D2R. Several reports have already proven the 
expression of ERK and PI3K in PC12 (43, 55, 58, 115) and MDCK cells (56, 60, 116) 
which made these two cell lines suitable for our study. 
Inhibition of ERK activation was conducted by applying a short cell permeable 
peptide which corresponds to the N-terminus of MEK (MAP kinase kinase). This 
membrane permeable peptide selectively binds to ERK and prevents its interaction 
with MEK and thereby has no effect on JNKs (Jun N-terminal Kinase) or p38 MAP 
kinase which makes it more suitable for specific inhibition of ERK activation in 
comparison to the common pharmacological inhibitors (59). Inhibition of ERK 
activation reduced the genotoxic effect of dopamine, which can be attributed to the 
decreased ability of DAT to take up dopamine (44 % in MDCK-DAT cells upon ERK 
inhibition) (34). Inhibition of PI3K by wortmannin also reduced the dopamine-induced 
DNA damage and measurement of dopamine uptake after wortmannin treatment also 
showed a decrease to 59 % which may account for the impeded genotoxic damage. 
We also observed a reduction of dopamine uptake after treatment with the D2R 
antagonist sulpiride (to 67 %). This reduction confirmed our results from 
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immunocytochemistry where we could show that sulpiride was able to reduce 
dopamine-induced migration of DAT from the cytosol to the membrane. This agrees 
with another report describing the effect of D2R antagonism on DAT localization 
using other methods (74). 
Our results from reduction of DAT activity after PI3K inhibition are in accordance with 
some previous reports (19) but Bolan and co-workers (12) suggested that DAT 
regulation by D2R is PI3K independent. It is important to consider that our 
observation here is probably the mixed effect of D2/D3 receptors. Regulation of DAT 
by D2 and D3 receptors may take place at least in part through different mechanisms 
(118). The last report also stresses that inhibition of PI3K does not influence 
phosphorylation of MAPK induced by D3 signaling. Therefore, the effect of PI3K on 
DAT regulation can be considered MAPK independent. In our model we cannot 
distinguish between the roles of D2 or D3 receptors in the genotoxicity of dopamine. 
More investigations would have to be conducted to clarify this aspect. 
Several other groups have measured the physiological and pathophysiological 
concentration of dopamine in plasma or other body fluids. The values for 
physiological concentrations lie usually in the nanomolar range but these values can 
change extremely under pathophysiological conditions. One study reports values 
around 20 and 35 µM in blood and cerebrospinal fluid respectively of elderly 
individuals which were suspected for Alzheimer’s disease (51). In vitro we showed 
that in some cell lines even the dopamine concentration of 6.25 µM can lead to 
significant DNA damage. It still needs to be determined whether and at which 
concentration of dopamine there is a threshold for our observed mechanisms. 
In conclusion, the present results show that dopamine can cause genotoxicity in vitro. 
There are also indications of oxidative lesions in PD patients under L-Dopa therapy. 
The uptake of dopamine via DAT is the key component of dopamine-induced 
genotoxicity. Once inside the cells, dopamine undergoes deamination, mainly by 
MAO, which leads to the production of ROS as by-products. These ROS are a major 
cause of the observed DNA damage in our system. D2R signaling is involved in this 
action via G-protein mediated activation of PI3K and ERK which ultimately results in 
higher activation and cell surface expression of DAT and hence elevated dopamine 
uptake. According to these findings, the proposed model of dopamine-induced 
genotoxicity is illustrated in Figure 59. 
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Figure 59 Model of signaling in dopamine-induced DNA damage. DA = dopamine, D2R = 
dopamine type 2-like receptor, Gαi/o = G-protein subunits Gαi/o, PI3K = Phosphoinositide 3-
kinase , ERK1/2 = extracellular signal-regulated kinases, DAT = dopamine transporter, MAO = 
monoamine oxidase, ROS = reactive oxygen species. 
 
It is known from the study of several hormones and cytokines that endogenous 
compounds are able to produce ROS and in some cases DNA damage (101). In the 
current work, we focused on two compounds which mostly exert their effect in the 
body via GPCR signaling. In the case of Ang II, the genotoxic effect is completely 
receptor dependent and the pathway which starts with the stimulation of the AT1R 
eventually leads to the formation of DNA damage. For dopamine, although the 
stimulation of the receptor is not enough to induce genomic damage, the receptor 
signaling enhances the genotoxicity of dopamine by affecting the localization of DAT 
and dopamine uptake. Therefore, we claim that our study provides evidence for 
receptor-mediated genotoxicity of two compounds with different mechanism of 
actions. Due to the involvement of the GPCR signaling in several pathways of 
physiological as well as pathological processes, it still has to be investigated whether 
receptor-mediated oxidative stress and subsequent DNA damage can trigger new 
complications which adds to the conditions that patients already suffer from.  
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6 Abstract 
 
Reactive oxygen species (ROS) are continuously generated in cells and are involved 
in physiological processes including signal transduction but also their damaging 
effects on biological molecules have been well described. A number of reports in the 
literature implicate excessive oxidative stress and/or inadequate antioxidant defense 
in the pathogenesis of cancer, atherosclerosis, chronic and age related disorders.  
Several studies have indicated that activation of the renin-angiotensin-aldosterone-
system can lead to the formation of ROS. Epidemiological studies have revealed 
higher renal cell cancer incidences and also higher cancer mortalities in hypertensive 
individuals. Recently, our group has shown that perfusion of the isolated mouse 
kidney with Ang II or treatment of several cell lines with Ang II leads to formation of 
DNA damage and oxidative base modifications. Here, we tried to scrutinize the 
pathway involved in genotoxicity of Ang II. 
We confirmed the genotoxicity of Ang II in two kidney cell lines of human origin. Ang 
II treatment led to the production of superoxide anions which we could hinder when 
we used the membrane permeable superoxide dismutase (SOD) mimetic TEMPOL. 
One of the enzymes which is activated in the cells after Ang II treatment and is able 
to produce ROS is NADPH oxidase. Phosphorylation of p47 subunit of NADPH 
oxidase after Ang II treatment was enhanced. Using two inhibitors we showed that 
NADPH oxidase inhibition completely prevents DNA damage by Ang II treatment. To 
differentiate between Nox2 and Nox4 isoforms of NADPH oxidase subunits in the 
genotoxicity of Ang II, we performed siRNA inhibition and found a role only for Nox4, 
while Nox2 was not involved.  
Next, we investigated PKC as a potential activator of NADPH oxidase. We showed 
that PKC becomes phosphorylated after Ang II treatment and also that inhibition of 
PKC hinders Ang II from damaging the cells. Our results from using several inhibitors 
of different parts of the pathway revealed that PKC activation in this pathway is 
dependent on the action of PLC on membrane phospholipids and production of IP3. 
IP3 binds to its receptor at endoplasmic reticulum (ER), opening a channel which 
allows calcium efflux into the cytoplasm. In this manner, both ER calcium stores and 
extracellular calcium cooperate so that Ang II can exert its genotoxic effect. PLC is 
activated by AT1R stimulation. We could also show that the genotoxicity of Ang II is 
mediated via AT1R signaling using the AT1R antagonist candesartan.  
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In conclusion, here we have shown that Ang II is able to damage genomic damage 
in cell lines of kidney origin. The observed damage is associated with production of 
ROS. A decrease in Ang II-induced DNA damage was observed after inhibition of G-
proteins, PLC, PKC and NADPH oxidase and interfering with intra- as well as 
extracellular calcium signaling. This leads to the following preliminary model of 
signaling in Ang II-induced DNA damage: binding of Ang II to the AT1 receptor 
activates PLC via stimulation of G-proteins, resulting in the activation of PKC in a 
calcium dependent manner which in turn, activates NADPH oxidase. NADPH 
oxidase with involvement of its Nox4 subunit then produces reactive oxygen species 
which cause DNA damage. 
 
Dopamine content and metabolism in the peripheral lymphocytes of PD patients are 
influenced by L-Dopa administration. The PD patients receiving a high dose of L-
Dopa show a significantly higher content of dopamine in their lymphocytes 
compared to PD patients who received a low dose of L-Dopa or the healthy control. 
Central to many of the processes involved in oxidative stress and oxidative damage 
in PD are the actions of monoamine oxidase (MAO), the enzyme which is 
responsible for the enzymatic oxidation of dopamine leading to production of H2O2 
as a by-product. We investigated whether dopamine oxidation can cause 
genotoxicity in lymphocytes of PD patents who were under high dose L-Dopa 
therapy and afterward questioned the occurrence of DNA damage after dopamine 
treatment in vitro and tried to reveal the mechanism by which dopamine exerts its 
genotoxic effect. The frequency of micronuclei in peripheral blood lymphocytes of 
the PD patients was not elevated compared to healthy age-matched individuals, 
although the formation of micronuclei revealed a positive correlation with the daily 
dose of L-Dopa administration in patients who received L-Dopa therapy together 
with dopamine receptor agonists. 
In vitro, we describe an induction of genomic damage detected as micronucleus 
formation by low micromolar concentrations in cell lines of different tissue origins. 
The genotoxic effect of dopamine was reduced by addition of the antioxidants 
TEMPOL and dimethylthiourea which proved the involvement of ROS production in 
dopamine-induced DNA damage. To determine whether oxidation of dopamine by 
MAO is relevant in its genotoxicity, we inhibited MAO with two inhibitors, trans-2-
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phenylcyclopropylamine hydrochloride (PCPA) and Ro 16-6491 which both reduced 
the formation of micronuclei in PC12 cells. 
We also studied the role of the dopamine transporter (DAT) and dopamine type 2 
receptor (D2R) signaling in the genotoxicity of dopamine. Inhibitors of the DAT, GBR-
12909 and nomifensine, hindered dopamine-induced genotoxicity. These results 
were confirmed by treatment of MDCK and MDCK-DAT cells, the latter containing the 
human DAT gene, with dopamine. Only MDCK-DAT cells showed elevated 
chromosomal damage and dopamine uptake. Although stimulation of D2R with 
quinpirole in the absence of dopamine did not induce genotoxicity in PC12 cells, 
interference with D2R signaling using D2R antagonist and inhibition of G-proteins, 
phosphoinositide 3 kinase and extracellular signal-regulated kinases reduced 
dopamine-induced genotoxicity and affected the ability of DAT to take up dopamine. 
Furthermore, the D2R antagonist sulpiride inhibited the dopamine-induced migration 
of DAT from cytosol to cell membrane. 
Overall, the neurotransmitter dopamine causes DNA damage and oxidative stress in 
vitro. There are also indications that high dose L-Dopa therapy might lead to 
oxidative stress. Dopamine exerts its genotoxicity in vitro upon transport into the cells 
and oxidation by MAO. Transport of dopamine by DAT has the central role in this 
process. D2R signaling is involved in the genotoxicity of dopamine by affecting 
activation and cell surface expression of DAT and hence modulating dopamine 
uptake. 
 
We provided evidence for receptor-mediated genotoxicity of two compounds with 
different mechanism of actions. The involvement of these receptors in many human 
complications urges more investigations to reveal whether abnormalities in the 
endogenous compounds-mediated signaling can play a role in the initiation of new 
conditions like carcinogenesis.  
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7 Zusammenfassung 
Reaktive Sauerstoffspezies (ROS) werden kontinuierlich in Zellen generiert und sind 
an physiologischen Prozessen wie der Signaltransduktion beteiligt. Aber auch ihre 
schädigenden Auswirkungen auf biologische Moleküle sind seit langem bekannt. 
Eine Reihe von Literaturberichten sieht einen Zusammenhang zwischen 
übermäßigem oxidativen Stress oder einer unzureichenden antioxidativen 
Verteidigung und Krebs, Atherosklerose und chronischen bzw. altersbedingten 
Erkrankungen. Mehrere Studien haben belegt, dass die Aktivierung des Renin-
Angiotensin-Aldosteron-Systems zur Bildung von ROS führen kann. 
Epidemiologische Studien haben gezeigt, dass Nierenkarzinom-Inzidenzen und 
Mortalitäten bei Hypertonikern erhöht sind. Vor kurzem konnte unsere Gruppe zeigen, 
dass die Perfusion von isolierten Mäusenieren und die Behandlung mehrerer 
Zelllinien mit Angiotensin II (Ang II) zur Bildung von DNA-Schäden und oxidativen 
Basenmodifikationen führt. Ziel der vorliegenden Arbeit war es, die Signalwege der 
Genotoxizität von Ang II zu bestimmen. Die Genotoxiziät von Ang II in zwei Nieren-
Zelllinien humaner Herkunft konnte bestätigt werden. Wir zeigten, dass Ang II-
Behandlung zur Produktion von Superoxid-Anionen führt, die durch das 
membrangängige Superoxid-Dismutase-Mimetikum TEMPOL verhindert werden 
kann. Eines der Enzyme, das in den Zellen nach Ang II-Behandlung aktiviert wird und 
ROS produzieren kann, ist die NADPH-Oxidase. Die mittels RT-PCR gemessene 
Hochregulierung von p47 beweist die Aktivierung der NADPH-Oxidase nach Ang II-
Behandlung. Auch die Phosphorylierung von p47 nach Ang II-Behandlung wurde 
gesteigert. Mittels zweier Inhibitoren zeigten wir, dass NADPH-Oxidase-Hemmung 
DNA-Schäden durch Ang II-Behandlung vollständig verhindert. Wir versuchten, die 
Rolle der Nox2- und Nox4-Isoformen der NADPH-Oxidase-Untereinheiten bei der 
Genotoxizität von Ang II zu differenzieren. Hemmung mittels siRNA bestätigte nur 
eine Beteiligung der Nox4. Anschließend überprüften wir die Rolle der PKC als 
potentiellem Aktivator der NADPH-Oxidase. Wir zeigten, dass die PKC nach Ang II-
Behandlung phosphoryliert wird und durch die Hemmung der PKC Ang II-induzierte 
Schäden verhindert werden. Die Verwendung mehrerer Inhibitoren der 
verschiedenen Teile des Signalweges zeigte, dass die PKC-Aktivierung von der 
Reaktion der PLC mit Membranphospholipiden und der Produktion von IP3 und DAG 
abhängig ist. IP3 bindet an seinen Rezeptor am Endoplasmatischen Retikulum (ER). 
Die in der Folge auftretende Öffnung eines Kanals ermöglicht einen Calcium-
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Ausstrom in das Cytoplasma. Auf diese Weise sind sowohl ER-Calcium als auch 
extrazelluläres Calcium an der Ang II-induzierten genotoxische Wirkung beteiligt. 
PLC wird durch AT1R-Stimulation aktiviert. Wir konnten mit Hilfe des AT1R-
Antagonisten Candesartan auch zeigen, dass die Genotoxizität von Ang II über 
AT1R-Signaltransduktion vermittelt wird. 
Zusammenfassend haben wir gezeigt, dass Ang II genomische Schäden in humanen 
Nieren-Zelllinien verursacht. Die Schäden sind mit der Produktion von ROS 
verbunden. Eine Reduktion der Ang II-induzierten DNA-Schäden wurde nach 
Hemmung von G-Proteinen, der PLC, PKC und NADPH-Oxidase und Beeinflussung 
intra- sowie extrazellulärer Calium-Signalgebung gezeigt. Dies führt zu folgendem 
vorläufigen Modell der Signaltransduktion der von Ang II-induzierten DNA-Schäden: 
Die Bindung von Ang II an AT1R aktiviert die PLC durch Stimulierung der G-Proteine 
und die PKC in Calcium-abhängiger Weise, dies wiederum aktiviert die NADPH-
Oxidase. Die NADPH Oxidase unter Beteiligung ihrer Nox4-Untereinheit erzeugt 
dann reaktive Sauerstoffspezies, die DNA-Schäden verursachen. 
 
Dopamingehalt und -stoffwechsel in peripheren Lymphozyten von Parkinson-
Patienten werden durch L-Dopa-Gabe beeinflusst. Die Patienten, die eine hohe 
Dosis L-Dopa erhalten, zeigen einen signifikant höheren Gehalt an Dopamin in den 
Lymphozyten im Vergleich zu Patienten, die eine niedrige Dosis L-Dopa erhalten 
oder der gesunden Kontrollgruppe. Im Mittelpunkt vieler Prozesse bei der Entstehung 
von oxidativem Stress und oxidativer Schäden bei Parkinson-Patienten steht die 
Monoaminoxidase (MAO), die für die enzymatische Oxidation von Dopamin und in 
der Folge für die Entstehung von H2O2 verantwortlich ist. Wir untersuchten, ob die 
Oxidation von Dopamin genotoxische Wirkung in Lymphozyten von Parkinson-
Patienten mit hochdosierter L-Dopa-Therapie induzieren kann. Danach überprüften 
wir, ob die Behandlung mit Dopamin in vitro DNA-Schäden induzieren kann und 
versuchten aufzuzeigen, durch welchen Mechanismus Dopamin seine genotoxische 
Wirkung entfaltet.  
Die Häufigkeit von Mikrokernen in peripheren Lymphozyten der Parkinson-Patienten 
war nicht erhöht im Vergleich zur gesunden Kontrollgruppe, allerdings zeigte die 
Mikrokernfrequenz eine positive Korrelation mit der täglichen L-Dopa-Dosis bei 
Patienten, die eine L-Dopa-Therapie zusammen mit einem Dopamin-Rezeptor-
Agonisten erhielten. 
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In vitro beobachteten wir bei niedrigen mikromolaren Konzentrationen eine Induktion 
des genomischen Schadens in Zelllinien, die aus verschiedenen Geweben stammten. 
Die genotoxische Wirkung von Dopamin wurde durch Zugabe der Antioxidantien 
TEMPOL und DMTU reduziert, wodurch die Beteiligung von ROS gezeigt werden 
konnte. Um festzustellen, ob die Oxidation von Dopamin durch MAO für die 
Genotoxizität relevant ist, hemmten wir MAO mit zwei Inhibitoren, trans-2-
Phenylcyclopropylamin-Hydrochlorid (PCPA) und Ro 16-6491, die beide die Bildung 
von Mikrokernen in PC-12-Zellen reduzieren konnten. Wir untersuchten auch die 
Rolle des Dopamin-Transporters (DAT) und Dopamin-Typ-2-Rezeptor (D2R)-
assoziierter Signalwege in der Genotoxizität von Dopamin. Die Inhibitoren des DAT, 
GBR-12909 und Nomifensin verhinderten die Dopamin-induzierte Genotoxizität. 
Diese Ergebnisse wurden durch Behandlung von MDCK- und MDCK-DAT- Zellen 
(die das humane DAT-Gen besitzen) mit Dopamin bestätigt. Nur MDCK-DAT-Zellen 
zeigten erhöhte chromosomale Schäden und Dopaminaufnahme. Obwohl die 
Stimulation mit dem D2R-Rezeptor-Agonisten Quinpirol in Abwesenheit von Dopamin 
keine Genotoxizität in PC-12-Zellen induzierte, reduzierten sowohl ein D2R-
Antagonist, wie auch Inhibitoren des in der Signalkaskade involvierten G-Proteins, 
der Phosphoinositol-3-Kinase und der extrazellulären signalregulierten Kinasen die 
Aufnahme von Dopamin mittels DAT und die Dopamin-vermittelte Genotoxizität. Der 
D2R-Antagonist Sulpirid hemmte die Dopamin-induzierte Migration von DAT aus dem 
Cytosol zur Zellmembran. 
Insgesamt verursacht der Neurotransmitter Dopamin DNA-Schäden und oxidativen 
Stress in vitro. Es gibt Hinweise, dass eine hochdosierte L-Dopa-Therapie zu 
oxidativem Stress führt. In vitro führt Dopamin zu Genotoxizität durch Transport in die 
Zellen und Oxidation durch MAO. Der Transport von Dopamin durch DAT spielt eine 
zentrale Rolle in diesem Prozess. Die D2R-Signalwege sind an der Genotoxizität  
von Dopamin durch Auswirkung auf die Aktivierung und Membranexpression von 
DAT und damit der Dopaminaufnahme beteiligt. 
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